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The simplest approach to the study of an event is to first consider that of the simplest cause. 
When investigating the mechanisms governing idiopathic diseases, this generally takes the form 
of an ab initio genetic approach, often in search of a single genetic culprit. To date, this genetic 
‘smoking gun’ has remained elusive for many affected by diabetes mellitus and a number of 
neurodegenerative diseases. With no single gene, or even subset of genes, found to be causative 
in all cases, other approaches to studying the etiology and treatment of these diseases seem 
reasonable. One such approach is considering trends consistently observed in diseases closely 
correlated with one another. In the cases of diabetes mellitus and neurodegenerative diseases, 
overlapping themes of mitochondrial influence or dysfunction and iron dyshomeostasis are 
apparent and relatively consistent.  This might suggest that gene networks involved in the 
maintenance of mitochondrial and iron related pathways are etiologically important. Thus, this 
dissertation focuses on a reductase, NCB5OR, whose absence has been shown to result in 
diabetes mellitus, mitochondrial dysfunction, and altered iron metabolism in mice.  Specifically, 
we focus on the effects of NCB5OR deficiency on mouse neural tissue as a means of exploring 
genes and pathways known to result in these overlapping trends. 
 In order to study the effects of NCB5OR deficiency on neural tissue and pathways we used 
mice globally deficient for NCB5OR (GKO) and also developed a conditional knockout mouse 
that inactivates NCB5OR in the cerebellum and midbrain (CKO).  Using either of these models, 
three questions were addressed: What effect does NCB5OR deficiency in the mouse cerebellum 
and midbrain have on iron homeostasis and locomotor behavior?  What effect does loss of 
NCB5OR in cerebellohypothalamic circuitry have on feeding behavior and metabolism?  Does 
iv 
 
loss of NCB5OR affect major neurotransmitters in the brains of mice globally deficient for 
NCB5OR? 
 Chapter 1 details background information on the MIND (mitochondria, iron, 
neurodegeneration, and diabetes) paradigm, which provides the context in which these studies 
were conducted. Although over 100 neurodegenerative diseases have been classified, the 
majority of the background presented will use Alzheimer’s disease (AD) as the model complex, 
idiopathic neurodegenerative disease, providing a focused example of the MIND paradigm 
framework. Also discussed is the incidence of diabetes accompanied by neuropathy and 
neurodegeneration along with neurodegenerative disorders prone to development of diabetes. 
Mouse models containing multiple facets of this overlap are also described alongside current 
molecular trends attributed to both diseases.  A detailed background pertaining to NCB5OR as 
well as known phenotypes and preliminary observations associated with its absence are 
presented. Finally, a review of  the cerebellum and its contribution to motor and higher order 
cognitive processes is presented so as to help better understand why the cerebellum was chosen 
as the primary model system for the study of NCB5OR in neural tissue.  
Chapters 2-4 address the above three questions with studies aimed at initial characterization 
of the effects of NCB5OR deficiency. Briefly, results from Chapter 2 demonstrate an altered 
state of iron homeostasis in the mouse cerebellum devoid of NCB5OR. Additionally, analysis of 
locomotor behavior revealed altered locomotor activity, proprioception, and sensitivity to 
harmaline-induced tremor in CKO mice.   Chapter 3 explores metabolic and behavioral changes 
in CKO mice which reveal the complex nature of NCB5OR deficiency on neural pathways that 
participate in feeding behavior and neural regulation of metabolism. Finally, Chapter 4 presents 
data that suggest that the absence of NCB5OR does not affect levels of serotonin (5-HT), 
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dopamine (DA), γ-aminobutyric acid (GABA), or glutamate (Glut) in the cerebellum but does 
increase levels of DA in the frontal cortex of mice globally deficient for NCB5OR. 
The primary purpose of this work is to contribute to the understanding of the complex 
nature and etiology of idiopathic neurological disease by providing evidence emphasizing 
the importance of genes whose function influences iron and metabolic homeostasis.  It is 
hoped that the data presented here helps to shed light on pathways and genetic networks whose 
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1.1 Mitochondria and Iron in Neurodegeneration and Diabetes (MIND) 
1.1.1 Borrowed Evolution: β-cells and neurons. Elements influencing the development of 
diabetes mellitus and a number of neurodegenerative and neurological disorders have been well 
established (see reviews (Swerdlow, 2009, 2011a)), however, given their complexity, a succinct 
analysis of major underlying themes spanning them has yet to be presented. Approximately 60–
70% of the 25.8 million Americans with diabetes develop neurological symptoms and damage 
(Prevention, 2011). Moreover, more than 20 neurodegenerative syndromes among the 100 
characterized so far are associated with diabetes mellitus (Ristow, 2004). In Alzheimer’s disease 
(AD) there is an approximately 35% diabetes incidence (Janson et al., 2004). Likewise, the 
presence of diabetes mellitus results in a 65% increased risk of AD (Arvanitakis, Wilson, 
Bienias, Evans, & Bennett, 2004) and  Parkinson’s disease (PD) (Hu, Jousilahti, Bidel, 
Antikainen, & Tuomilehto, 2007). In order to explore these trends and the polygenic networks 
potentially governing these diseases we are considering two common areas linking them: 
mitochondria and iron. We will start by making note of the inherent similarities between the 
neurological and endocrine systems.  
In 1869 Paul Langerhans identified and described the endocrine, or hormone secreting, 
cells of the pancreas (Langerhans, 1869). These clusters of cells have since been named the Islets 
of Langerhans and been described in detail. Islets are composed of 5 known cell types, each 
playing an independent role in endocrine regulation. In diabetes mellitus the insulin producing 
and secreting β-cells are of particular interest since these cells are generally dysfunctional or 
altogether destroyed in events preceding the onset of diabetes. Interestingly, β-cell dysfunction in 
diabetes might provide a unique opportunity when considering different etiological approaches 
to diseases like AD and PD. This is due, in part, to an evolving realization that β-cells and 
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neurons possess striking similarities, both functionally and in genetic profile. In 2011, Arntfield 
and van der Kooy summarized the similarities between neurons and β-cells and suggested that in 
an instance of convergent evolution, β-cells ‘‘borrowed from the brain’’ (Table 1.1) (Arntfield & 
van der Kooy, 2011; Fujita, Kobayashi, & Yui, 1980; Pearse & Polak, 1971)). Basically, neurons 
and β-cells are derived from different tissue layers (ectoderm and endoderm, respectively) but 
are very similar in the way that they store, respond to, and transmit signaling molecules. 
Knowledge of the similarities between β-cells and neurons has existed for some time (Atouf, 
Czernichow, & Scharfmann, 1997). As early as the 1970’s, it was discovered that the pancreas 
actually synthesizes, stores, and secretes γ-aminobutyric acid (GABA), a major inhibitory 
neurotransmitter (Thomas-Reetz & De Camilli, 1994). Further investigation revealed that β-cells 
store and release GABA through synaptic-like microvesicles (Reetz et al., 1991). In fact, glucose 
mediated secretion of GABA by β-cells inhibits glucagon release from alpha-cells (Rorsman et 
al., 1989). Conversely, acetylcholine, another major neurotransmitter, is released from alpha-
cells resulting in β-cells that are primed for adequate insulin response (Rodriguez-Diaz et al., 
2011). Similar to neurotransmitter release in neurons, insulin secretion in β-cells is accomplished 
via membrane depolarization as a result of external cues. In diabetes, primary metabolic 
processes governing glucose mediated insulin secretion are impaired. Comparatively, metabolic 
processes governing synaptic plasticity and transmission are dysfunctional or impaired in AD. It 
seems evident that diabetes mellitus and neurodegenerative diseases like AD and PD could be 
the result of similarly perturbed mechanisms that ultimately govern their pathology. Thus closer 
analysis of shared changes and defects between these two diseases could prove beneficial in 
identifying key networks involved in their pathology.  
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In essence, diabetes, AD, and PD are simply complex and result in consistently broad and 
inconclusive etiological studies. For this reason we are proposing that idiopathic cases arise 
through each system’s predisposed sensitivity to metabolic influence determined not by a single 
gene but rather by genetic networks whose composite function determines susceptibility. More 
accurately, we posit that changes in bioenergetic homeostasis, influenced largely by 
mitochondrial and iron related pathways, lie at the nexus of neurodegeneration and diabetes 
(Figure 1.1).  
As a way of approaching the idiopathic and complex nature of these diseases we are 
proposing the consideration of a MIND (mitochondria, iron, neurodegeneration, and diabetes) 
paradigm in which systemic metabolic influence, iron homeostasis, and respective genetic 
backgrounds play a central role in the development of disease.  
1.1.2 Forming the MIND Paradigm: Frataxin and the monogenic contributors 
Friedreich’s ataxia (FA) is a monogenic disease that provides a particularly elegant 
demonstration of the link between mitochondria and iron in the processes and pathways 
governing neurodegeneration and diabetes. Friedreich’s ataxia patients experience peripheral 
nerve and dorsal root ganglia atrophy, ataxia in all four limbs, dysarthria, cardiac abnormalities 
including arrhythmia, and diabetes mellitus. The primary cause of FA is a significant reduction 
in the availability of the mitochondria-localized protein frataxin as a result of a large GAA 
trinucleotide repeat expansion in the first intron of FXN (Campuzano et al., 1996; Durr et al., 
1996; Koutnikova et al., 1997). As is the case in other trinucleotide repeat disorders, it is 
postulated that this expansion results in either delayed transcription, altered transcript processing 
(E. Kim, Napierala, & Dent, 2011), or altered protein folding and translational efficiency like 
that observed in Huntington’s disease (Bauer & Nukina, 2009; Polling, Hill, & Hatters, 2012; 
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Robertson & Bottomley, 2012). Various studies suggest that frataxin is a key component in iron–
sulfur processing in the mitochondrial matrix (Adinolfi et al., 2009; Schmucker et al., 2011).  
Iron-sulfur clusters are key components to catalytically active subunits in the mitochondrial 
electron transport chain (ETC). A number of models for Friedreich’s ataxia have been 
developed, ranging from transgenic mice to immortalized and induced pluripotent stem cell cell 
lines (Perdomini, Hick, Puccio, & Pook, 2013; Puccio et al., 2001; Ristow et al., 2003).  
Other monogenic instances in diabetes and Alzheimer’s disease have been documented in 
the forms of subtypes and models, representing a small percentage of the population for which a 
single contributing factor can be identified (Andersen et al., 2004; Florez, Hirschhorn, & 
Altshuler, 2003; Haass et al., 1995; Hutton & Hardy, 1997; Shulman, De Jager, & Feany, 2011; 
W. Wang et al., 2011). Further examination reveals that many of these monogenic causes lie in 
major pathways contributing to metabolic flux, mitochondrial function, and regulation of iron 
metabolism and homeostasis (Duce et al., 2010; Hsu et al., 2000; Protter, Lang, & Cooper, 2012; 
Rogers et al., 2008; W. Wang et al., 2011; Xie et al., 2004).  
1.1.2a Monogenic events in diabetes 
 Maturity-onset diabetes of the young (MODY) and maternally inherited diabetes and 
deafness (MIDD) can be considered two major, albeit rare, monogenic forms of diabetes mellitus 
(Florez et al., 2003). In MIDD, a single AG mutation in the mitochondrial-encoded gene for 
tRNA leucine results in diabetes and deafness (van den Ouweland et al., 1994). In parallel, more 
than half of the 6 genes attributed to the development of MODY (Florez et al., 2003) impact 
features and pathways critical to proper metabolic function (H. Y. Wang, Antinozzi, Hagenfeldt, 
Maechler, & Wollheim, 2000; H. Y. Wang, Maechler, Antinozzi, Hagenfeldt, & Wollheim, 
2000). Monogenic cases of non-mitochondrial origin have been identified in patients with miss-
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sense polymorphisms in KCNJ11, a gene encoding a major subunit of the ATP-sensitive K
+
 
channel (Fischer et al., 2008). Other monogenic diabetes models include animals lacking TFAM 
and NCB5OR (Brehm, Powers, Shultz, & Greiner, 2012). In the latter case, no significant 
contribution has been assigned to mutations or variations within the diabetic population 
(Andersen et al., 2004), yet NCB5OR null mice develop lean diabetes at age 7 weeks as a result 
of β-cell demise and display gross mitochondrial morphological changes accompanied by altered 
lipid metabolism (Larade et al., 2008; W. Wang et al., 2011; Xie et al., 2004). Interestingly, 
naturally occurring missense mutations in human NCB5OR lead to improper folding and 
significantly reduced levels of intracellular NCB5OR (Kalman et al., 2013). Recent data also 
suggest that ablation of NCB5OR leads to iron dyshomeostasis (H. Zhu, Wang, & Wang, 2013). 
Preliminary findings indicate neuromuscular junction defects and behavioral changes associated 
with altered neurological function in NCB5OR null mice (Stroh et al., unpublished data).  Such 
cell-specific phenotypes from an otherwise non-cell-specific gene provide evidence that 
particular cell and tissue types may be more susceptible to particular genetic insult over others. 
This is a useful framework to study correlation and causation in disease.  
1.1.2b Monogenic events in neurological disease 
Alzheimer’s disease is the most prevalent neurodegenerative disorder, affecting 13% of 
the population over the age of 65 (Hebert, Scherr, Bienias, Bennett, & Evans, 2003). Mutations 
in the amyloid precursor protein (APP), the precursor to amyloid plaques which are ,at times, 
considered to be a possible cause of Alzheimer’s disease, have been associated with early onset, 
familial Alzheimer’s disease (FAD). The Swedish mutation in APP leads to premature and 
accelerated cleavage of APP by β-secretase resulting in accumulation of amyloid oligomers (β-
amyloids) (Haass et al., 1995). The toxicity and function of β-amyloids has long been debated 
7 
 
but recent evidence suggests that APP possesses ferroxidase and iron export activity (Duce et al., 
2010), which may indicate APP normally participates in iron homeostasis. Regulatory elements 
in the APP mRNA directly link its function to the cellular iron status (Rogers et al., 2008).  
One of the best known genetic contributors to late onset Alzheimer’s disease (LOAD) is 
that of the APOEe4 allele. Patients who possess APOEe4 have a significantly elevated risk of 
developing LOAD, and account for approximately 40% of the LOAD population (Liu, 
Kanekiyo, Xu, & Bu, 2013). Carriers of the APOEe4 allele also demonstrate a reduced ability to 
clear Aβ42 amyloid deposits when compared to those possessing the e2 and e3 alleles 
(Castellano et al., 2011). Interestingly, evidence outlining metabolic brain abnormalities in 
young and old APOEe4 carriers alike suggests that metabolic decline, mitochondrial 
dysfunction, and eventual hypometabolism are critical risk factors in the development of 
APOEe4 associated LOAD (Alexander, Chen, Pietrini, Rapoport, & Reiman, 2002; Liang et al., 
2008; Minoshima, Foster, & Kuhl, 1994; Reiman et al., 2001; Reiman et al., 1996; Reiman et al., 
2004; Valla, Berndt, & Gonzalez-Lima, 2001; Valla et al., 2010). Less robust cognitive test 
performance in individuals harboring the allele can be observed in middle adulthood (Bloss, 
Delis, Salmon, & Bondi, 2008). These observations lend to the notion that changes in the 
metabolic environment occur much earlier than the development of the histological hallmarks of 
Alzheimer’s disease, pointing to possible upstream pathologies.  
1.1.3 Mitochondria and iron in sporadic neurological disease 
 Neurodegeneration is a generalized term used to describe loss of neuronal mass, locally 
or globally, as well as systemic malfunction and eventual loss of efficient neural transduction 
and communication. In either case, these events can result from changes in extra-neuronal 
networks by which the ideal neural environment is maintained, as is the case in multiple sclerosis 
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(Makris, Piperopoulos, & Karmaniolou, 2013), to changes in individual neuronal environments 
directly impacting their function. While it is obvious that genetic background plays a significant 
role in both mechanisms, contemplating the impact of compounded genetic variability (variable 
genetic networks) on disease susceptibility is not so trivial. Changes in metabolic function and 
iron regulation are observed in a number of neurological diseases yet the diseases remain 
pathologically distinct (Ponka, 2004). For this reason, variables governing mitochondrial 
function and iron regulation warrant further investigation. While many neurodegenerative 
diseases possess abnormalities in mitochondria and iron homeostasis, our focus will largely 
remain on changes in Alzheimer’s disease. 
In AD, the complexity of the disease is unmistakable with progressive cognitive decline 
consistently out of sync with historical pathological mechanisms like altered APP processing and 
amyloid fibril formation. In fact, significant amyloid plaque burden can be detected in elderly, 
but cognitively normal, individuals (Vlassenko et al., 2011). Even so, the most current and 
popular approaches to investigation and treatment are to simply analyze, understand, and 
eventually remove amyloid plaque deposits. So far this strategy has yielded negative or 
inconclusive results in clinical trials. Amyloid β oligomer deposition is a unique characteristic 
ascribed to Alzheimer’s disease, however, inconsistencies in the effects of senile plaques call for 
reassessing the role of toxic amyloid species in AD etiology (Pimplikar, 2009). Not discounting 
the downstream role of APP processing in the pathogenesis of Alzheimer’s disease, we would 
like to focus on pathways that are potential targets for therapeutic intervention prior to amyloid 
deposition and which aim to clarify susceptibility to the more common form of Alzheimer’s 
disease, LOAD. With the aforementioned correlation between Alzheimer’s disease and diabetes 
mellitus we will explore pathways that influence both diseases.  
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1.1.3a Mitochondrial and metabolic influence 
Mitochondrial-derived metabolic dysfunction has been documented in multiple 
neurodegenerative disorders (A. C. Belin et al., 2007; Swerdlow, 2009; Trimmer et al., 2000). 
One of the most recognized of these disorders is Alzheimer’s disease, for which a mitochondrial 
cascade hypothesis has been proposed (Swerdlow, Burns, & Khan, 2010, 2013; Swerdlow & 
Khan, 2004, 2009). Altered function in critical citric acid cycle components and ETC complexes 
as well as altered glucose metabolism and insulin resistance have all been observed in AD 
(Gibson et al., 1988; Perry, Perry, Tomlinson, Blessed, & Gibson, 1980; Sorbi, Bird, & Blass, 
1983; Steen et al., 2005). It has even been suggested that Alzheimer’s disease is in fact a form of 
type III diabetes (S. De La Monte, Wands JR. , 2008; S. M. de la Monte, 2014). This hypothesis 
is based on evidence of impaired insulin response pathways and insulin resistance in the 
Alzheimer’s brain (Steen et al., 2005; Talbot et al., 2012). The most reported functional 
deficiencies in ETC complexes arise in complex IV (cytochrome c oxidase; COX) Vmax 
activities, with complex I and III activities closely following suit. Reduced complex IV activity 
was first reported in mitochondria isolated from AD subject platelets (Parker, Filley, & Parks, 
1990). Further investigations probing COX activity in the AD brain also showed decreased 
activity similar to that observed in platelet-derived mitochondria (Kish et al., 1992; Mutisya, 
Bowling, & Beal, 1994) . This raised questions as to whether mitochondrial dysfunction could 
influence neurofibrillary tangles and amyloid plaque deposition. Early studies provided evidence 
that altered metabolism impacted APP processing (Gabuzda, Busciglio, Chen, Matsudaira, & 
Yankner, 1994; Gasparini et al., 1997). Cytoplasmic hybrid (cybrid) studies, in which platelet 





(neuroblastoma or teratocarcinoma) cells, have also reported changes in APP processing and 
amyloid species production (Khan et al., 2000; Swerdlow, 2007).  
In addition, cybrid studies show a profound shift in overall cellular bioenergetic 
equilibrium with reductions in membrane potential and altered calcium homeostasis (Swerdlow, 
2007). Changes in calcium homeostasis are consistent with changes in mitochondrial regulatory 
pathways and support observations that mice harboring presenilin 1 mutations, an established 
cause of familial AD (FAD), display mitochondrial dysfunction and altered cytosolic calcium 
homeostasis (Schneider, Zorzi, & Nardocci, 2013). Such observations also provide evidence for 
mitochondria as an upstream affecter in the production of β-amyloid since altered amyloid 
processing has been correlated with altered calcium homeostasis (Lee et al., 2013). Although 
there are conflicting accounts as to whether amyloid itself induces or alters the calcium changes 
observed in AD (Briggs, Schneider, Richardson, & Stutzmann, 2013), cybrid studies provide 
insight into mechanisms that may nurture β-amyloid production prior to its potential effects on 
intracellular calcium.  
It is widely accepted that ETC activity naturally produces reactive oxygen species (ROS) 
(Grivennikova & Vinogradov, 2006; Tan, Sagara, Liu, Maher, & Schubert, 1998). Reactive 
oxygen species production and oxidative stress rapidly increases during times of cellular stress 
and mitochondrial dysfunction, leading to significant damage to cellular organelles and DNA. 
The frontal cortex of AD patients display oxidative stress (Ansari & Scheff, 2010) along with 
increased levels of 8-hydroxydeoxyguanosine and 8-hydroxyguanosine in DNA and RNA, 
respectively (Quinlan, Perevoshchikova, Hey-Mogensen, Orr, & Brand, 2013), which are also 
indicative of oxidative stress. Recently, investigators demonstrated that, while multiple 
components of the ETC are sites of ROS production, the contribution to total ROS production 
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from each site depends largely on the substrates being oxidized and not solely upon the protein 
function per se (Quinlan et al., 2013). This provides further insight into possible dietary and 
environmental factors that were not considered in previous studies.  
Modes of inheritance for Alzheimer’s disease and Parkinson’s disease are sparsely 
Mendelian, lending to investigations of inheritance patterns in non-monogenic populations. 
These investigations have yielded ample data suggesting a maternal pattern of inheritance in 
Alzheimer’s disease (Duara et al., 1993; Edland et al., 1996; Mosconi et al., 2010) [119–121], 
consistent with maternal inheritance of mitochondrial DNA (mt-DNA) (Giles, Blanc, Cann, & 
Wallace, 1980). These observations in whole support a mitochondrial cascade hypothesis in 
which mitochondria and cell bioenergetics lie at the forefront of AD pathology.  
1.1.3b Iron dyshomeostasis in neurological disease 
 Iron metabolism and dyshomeostasis are implicated in a number of neurodegenerative 
disorders, including Parkinson’s disease (PD), Alzheimer’s disease (PD), neuroferritinopathy, 
aceruloplasminaemia, and neurodegeneration with brain iron accumulation (Ponka, 2004). 
Among them, AD and PD are the most prevalent forms without a single known cause. The role 
for iron in the pathogenesis of PD is being investigated but remains elusive with changes in iron 
and iron regulatory pathways consistently observed but spatially and temporally diffuse (Gotz, 
Double, Gerlach, Youdim, & Riederer, 2004). However, ample evidence supports consistent 
changes in redox-active metals in the brains of AD patients (Atwood, Huang, Moir, Tanzi, & 
Bush, 1999; X. D. Huang et al., 1999).  
 Early reports of iron accumulation in the AD brain (Goodman, 1953) have led to interest 
in the interaction and association of iron with the histological hallmarks of the disease: 
neurofibrillary tangles (NFTs) containing hyperphosphorylated tau and Aβ-containing senile 
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plaques. Iron accumulation in NFTs and amyloid plaques, as well as in the broader cortex, have 
been observed in AD patients and AD transgenic mouse models (M. A. Smith, P. L. Harris, L. 
M. Sayre, & G. Perry, 1997; Smith et al., 1998). Hyperphosphorylated tau-associated NFT 




, respectively (Yamamoto 
et al., 2002). In 2010, Duce et al. addressed questions surrounding the function of APP by 
demonstrating ferroxidase activity in ‘‘a conserved H-ferritin-like active site’’ within APP (Duce 
et al., 2010). It was concluded that APP loads oxidized iron into transferrin and demonstrates a 
significant interaction with ferroportin. These authors also reported the inhibition of APP 
mediated iron export by Zn
2+
. Most relevant to observations in AD patients, APP knockout mice 
demonstrated insufficient iron export capacity and significant retention of iron in cortical 
neurons (Behl, Davis, Lesley, & Schubert, 1994; Harris, Hensley, Butterfield, Leedle, & Carney, 
1995; X. D. Huang et al., 1999). The intracellular retention of iron likely potentiates a toxic 
cascade since Aβ-mediated reduction of iron has been shown to generate ROS, which in turn 
leads to increases in both APP and Aβ production (Behl et al., 1994; Harris et al., 1995; X. D. 
Huang et al., 1999). Recently, it was discovered that increased iron content from brain 
microbleeds enhanced the neurotoxic effects of Aβ (L. Wang, Xi, Keep, & Hua, 2012). Also, 
changes in serum iron and copper homeostasis were found to correlate and accurately predict 
cognitive decline (Mueller et al., 2012). It seems evident that iron’s role in the pathogenesis of 
AD lies either upstream or in tandem with Aβ accumulation. In comparison, the latter seems less 
likely as over expression of APP in trisomy 21 does not result in early life fibrillary amyloid 
accumulation (Arai, Suzuki, Mizuguchi, & Takashima, 1997). Instead, it is more likely that the 
effect of iron accumulation on Aβ-induced toxicity is the result of progressive insult to cellular 
iron processing.  
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Iron–sulfur clusters (ISCs) and heme are iron-containing prosthetic groups at the catalytic 
centers of many critical metabolic enzymes, including all four of the mitochondrial ETC 
complexes, and are essential to enzymes responsible for H2O2 removal and maintaining general 
cellular homeostasis. Mitochondria serve as the center stage for synthesis of ISCs and heme 
(Furuyama, Kaneko, & Vargas, 2007). As discussed earlier, mitochondrial and metabolic 
dysfunction are observed early in AD (Horowitz & Greenamyre, 2010). Normally, aging is 
accompanied by increased mt-DNA copy number, which is likely a compensatory mechanism 
for an aged and dysfunctional mitochondrial population (Barrientos et al., 1997) (Corral-
Debrinski et al., 1992). However, in the late stages of AD, amplifiable levels of intact mt-DNA 
are reduced, possibly through down regulation of PGC1α and mitophagy-induced degradation of 
mitochondria (Swerdlow & Kish, 2002). Given the relationship between iron, APP, and senile 
plaques, it seems likely that the intracellular recycling of large amounts of iron containing 
mitochondrial protein coupled with reduced APP, and thus reduced or impaired iron export 
capability, may compound bioenergetic decline in Alzheimer’s disease. 
1.1.4 Mitochondria and iron in idiopathic diabetes 
Diabetes mellitus can be characterized as a metabolic disorder for which three major 
types are known: Type 1 (T1D), Type 2 (T2D), and gestational diabetes mellitus. Type 1 
diabetes (or insulin dependent diabetes mellitus) manifests as the result of autoimmune targeted 
destruction of insulin-producing β-cells in the pancreatic islets, leading to progressive loss of 
insulin secretion and resulting in absolute insulin deficiency. Type 2 diabetes (most often 
associated with obesity) is characterized as hyperglycemia in the context of insulin resistance 
and relative insulin deficiency. Gestational diabetes results in hyperglycemia and insulin 
resistance during the term of pregnancy in formerly non-diabetic women. Type 2 diabetes 
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accounts for 90% of diabetes mellitus cases, whereas Type 1 diabetes, gestational diabetes, and 
monogenic diabetes comprise the remaining 10%. 
Insulin is a 5.8 kDa hormone produced by pancreatic β-cells and in the brain whose 
production and release is in response to elevated blood glucose levels. Insulin stimulation results 
in multiple complex, dynamic changes and cascades within a cell, ranging from changes in 
metabolic pathways and bioenergetic flux to targeted transcriptional changes in the nucleus (for 
review see (Saltiel & Kahn, 2001)). A primary defect in diabetes mellitus is that of glucose 
intolerance due to changes in insulin response. Many different, and often opposing, theories have 
arisen in an attempt to target the cause of insulin resistance. However, due to the complexity and 
variation within the disease, limited progress has been made. Diabetes mellitus results in 
dramatic changes to global metabolic regulation and substrate utilization for reasons that are 
undetermined, however evidence suggests that disturbed mitochondrial function and iron 
homeostasis play an important role.  
1.1.4a Mitochondrial and metabolic influence 
 Type 2 diabetes is characterized by relative insulin resistance and impaired insulin 
secretion in the presence of glucose. Changes in insulin secretion and response suggest attempts 
to compensate for or regulate potentially harmful changes in metabolism. Mitochondria play a 
significant role in regulating insulin secretion in β-cells through regulating the ATP levels 
responsible for facilitating membrane depolarization and insulin granule, as well as anaplerosis 
coupled, exocytosis (for reviews see (Jitrapakdee, Wutthisathapornchai, Wallace, & MacDonald, 
2010; Maechler, 2013)). Rapid, dramatic changes in mitochondrial morphology upon glucose 
stimulated insulin secretion have been observed as well as GTP modulated insulin secretion via 
changes in mitochondrial metabolism and calcium homeostasis (Jhun, Lee, Jin, & Yoon, 2013) 
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(Kibbey et al., 2007). Changes in mitochondrial and metabolic status in events preceding the 
onset of diabetes have been recognized for some time and have led to multiple theories 
proposing different roles for the observed mitochondrial dysfunction. Interestingly, changes in 
lipid oxidation and fatty acid storage occur just prior to disease onset with increased lipolysis 
accompanied by changes in circulating free fatty acids (Lewis, Carpentier, Adeli, & Giacca, 
2002). It is debated whether this change constitutes a state of compensation or mitochondrial 
dysfunction. This mainly stems from inconsistent observations of the effects of fatty acid 
metabolism and altered mitochondrial function in different diabetic populations (i.e. obese vs. 
lean) (S. D. Martin & McGee, 2013) . Normally, glucose stimulated insulin secretion from β-
cells increases in the presence of fatty acids; however this has been shown to decrease during 
prolonged fatty acid exposure (Sako & Grill, 1990). In contrast, some studies have found that 
increased fatty acid availability stimulates mitochondria-mediated fatty acid oxidation in muscle 
(Lewis et al., 2002). This suggests that insulin resistance in the periphery is not necessarily a 
product of mitochondrial dysfunction, but rather a non-canonical shift in primary bioenergetic 
pathways based on substrate availability. Still, mitochondria play a critical role in regulating 
pathways mediating insulin secretion and response, making them central to investigations of 
perturbed bioenergetic flux in diabetes. 
 In 1901 Eugene Opie discovered protein deposition in the pancreas of patients with 
hyperglycemia, describing ‘‘hyaline degeneration of the islands of Langerhans’’ (Opie, 1901). It 
was not until 1986 that islet amyloid polypeptide (IAPP) was identified and found to be a 
primary component of these deposits (Westermark, Wernstedt, Wilander, & Sletten, 1986). It has 
since been discovered that more than 90% of patients with T2D display IAPP associated protein 
deposition in the pancreas (Hoppener, Ahren, & Lips, 2000; Westermark, 1994). The human 
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form of IAPP (hIAPP) is secreted with insulin, although its exact function remains unknown. 
Interestingly, IAPP and brain-associated APP share 90% structural similarity (Ristow, 2004; 
Westermark, 1994), with hIAPP also possessing structural characteristics that allow it to form 
amyloid fibrils. Human IAPP has been shown to induce loss of β-cell mass through 
mitochondrial dysfunction induced activation of apoptotic pathways (Li et al., 2011). Results 
regarding the potential of an FDA approved treatment for T2D in a transgenic FAD mouse 
model were released in September of 2013. Liraglutide, a glucagon mimetic and GLP-1 agonist 
used to stimulate insulin secretion in the presence of glucose, was shown to result in decreased 
tau phosphorylation, decreased neurofilament formation, and increased memory performance 
and ability in mice (Xiong et al., 2013). This is consistent with previous findings that 
demonstrated reduced plaque formation and oxidative stress in transgenic mice treated with 
GLP-1 (Holscher, 2013). It is not surprising that exendin-4, a GLP-1 agonist, protects β-cells 
from hIAPP-associated cell death through improved mitochondrial function and biogenesis (Fan, 
Li, Gu, Chan, & Xu, 2010). Exendin-4 also increases adult neurite outgrowth of sensory neurons 
(Kan, Guo, Singh, Singh, & Zochodne, 2012), a result important in addressing diabetic 
neuropathy (vide infra). To our knowledge, the effects of GLP-1 agonists on mitochondrial 
function and oxidative stress in the AD brain have yet to be studied, although these results 
provide reason to suspect altered and improved metabolic status as a result of GLP-1 receptor 
modulation.  
1.1.4b Iron homeostasis in diabetes 
 The effects of iron overload and dyshomeostasis in the pathophysiology of diabetes is 
relatively understudied. However, an increased interest has been generated with multiple groups 
finding an increased risk of Type 2 diabetes and insulin resistance associated with alterations in 
17 
 
tissue iron content, iron metabolism, and iron overload (Mendler et al., 1999; Simcox & 
McClain, 2013; M. C. Thomas, MacIsaac, Tsalamandris, & Jerums, 2004). Increased serum 
ferritin concentration, an indicator of tissue iron status, was positively correlated with the risk of 
developing T2D (Ford & Cogswell, 1999). More studies have confirmed the increased risk of 
diabetes with high normal or above normal serum ferritin levels and suggested that iron 
deficiency may not provide protection against this risk (Aregbesola, Voutilainen, Virtanen, 
Mursu, & Tuomainen, 2013). A recent study evaluating ferritin and transferrin saturation in pre-
diabetes concluded that high ferritin combined with low transferrin saturation was associated 
with a higher risk of developing prediabetes (Cheung, Cheung, Lam, & Cheung, 2012).  
Hereditary hemochromatosis, or iron overload, is commonly caused by mutations in the 
HFE gene and provides the strongest evidence of systemic iron changes leading to T2D. An 
allelic variant of HFE linked to hemochromatosis, termed the ‘D allele’, was shown to increase 
the risk for diabetes (Rong et al., 2012). HFE-associated diabetes suggests that changes in 
systemic iron homeostasis, particularly iron overload is associated with diabetes incidence. This 
has been strengthened with observations that dietary intake of red meat, a significant source of 
heme iron, is positively correlated with an increased risk of T2D (Jiang et al., 2004). Also, 
frequent blood donations and iron chelation therapy are shown to improve diabetes in T2D 
patients (Fernandez-Real, Lopez-Bermejo, & Ricart, 2005).  
With little indication as to the exact role of iron overload in the risk for diabetes it is 
difficult to say whether iron dyshomeostasis is a catalyst or artifact of the disease. Studies on 
frataxin and NCB5OR pathways will help to provide novel insights into roles for iron 




1.1.5 Alzheimer’s disease and diabetic neuropathy 
 Diabetic neuropathy is a generalized term describing changes and defects in the nervous 
system of patients diagnosed with diabetes mellitus. Diabetic neuropathy does not discriminate 
between T1D and T2D. Several forms exist and can be divided into two distinct groups: 
generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic), and 
focal and multifocal neuropathies (cranial, truncal, focal limb, proximal motor, chronic 
inflammatory demyelinating polyneuropathy) (Boulton et al., 2005). Numerous studies have 
observed changes in bioenergetic pathways and mitochondrial function in diabetic neuropathy-
associated neurodegeneration for both T1D and T2D (for reviews see (Chowdhury, Dobrowsky, 
& Fernyhough, 2011; Chowdhury, Smith, & Fernyhough, 2013)). In fact, improving 
mitochondrial bioenergetics through NF-kβ activation prevents sensory neuropathy in mouse 
models of T1D (Saleh et al., 2013). The glycolytic byproduct methylglyoxal, a reactive form of 
pyruvate that plays a role in the development of advanced glycation endproducts, is of particular 
interest to diabetes and diabetic neuropathy (Singh, Barden, Mori, & Beilin, 2001). Advanced 
glycation end products have been positively correlated with diabetic nephropathy along with a 
number of different diabetes associated complications (Beisswenger et al., 2013; Singh et al., 
2001). A recent investigation found that methylglyoxal mediated modification of the Nav1.8 
sodium channel is associated with hyperalgesia in diabetic neuropathy (Bierhaus et al., 2012), 
implicating a direct role for methylglyoxal in diabetes-induced nociceptive pain. In addition, a 
novel neurotoxin known as ADTIQ (1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) 
discovered in the brains of PD patients has been found to be the result of methylglyoxal reacting 
with dopamine (Deng et al., 2012). It has been suggested that this neurotoxin, the result of 
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altered bioenergetic homeostasis and a specific neurotransmitter, might be a common pathogen 
between Parkinson’s disease and diabetes. 
Both T1D and T2D result in impaired memory and learning, however the distinctions 
between T1D and T2D have led to much debate as to the underlying cause. Traditionally, 
impaired insulin signaling was primarily attributed to T2D and thought to be a larger risk factor 
for developing AD compared to T1D. However, recent studies have demonstrated worsened AD 
associated phenotypes in the context of T1D (Currais et al., 2012; Jolivalt et al., 2010), blurring 
the lines between T1D and T2D in AD. Still, little is known of the effects of AD on peripheral 
neuropathy. Interest has been generated due to reports of the underrepresented population of 
dementia patients who experience pain (C. Belin & Gatt, 2006), but it is not immediately clear 
whether pain associated with dementia is the result of true neuropathy or that of altered pain 
perception. In 2012, Jolivalt et al. provided physiological evidence that APP transgenic mice 
demonstrated ‘‘similar patterns of peripheral neuropathy’’ when compared to insulin-deficient 
mouse models (Jolivalt, Calcutt, & Masliah, 2012). This was attributed to impaired or altered 
insulin signaling through lowered insulin receptor phosphorylation as well as altered GSK3β-
mediated metabolic regulation. Changes in insulin signaling and regulation are found in both 
diabetes and AD (for review see (Sima & Li, 2006)). Deficiencies in metabolic processes and 
pathways are clearly identified in both diseases, thus the presence of peripheral neuropathy like 
phenotypes in AD mouse models suggests shared pathogenic mechanisms. 
1.1.6 Genetic variation, disease susceptibility, and potential therapeutics  
 A variety of neurodegenerative diseases display characteristics of MIND paradigm-
associated defects. Still, with all of the data presented and available, the polygenic nature of 
these diseases makes identifying viable therapeutic targets the rate limiting step in treatment. 
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Traditionally, successful treatment development relies on two inherent criteria: disease 
incidence/impact and identifiable therapeutic targets. In complex, sporadic diseases like 
Alzheimer’s disease or Parkinson’s disease, the incidence of the disease is profound and 
indisputable. However, progress falls short when treatment is focused on therapeutic targets 
which are not major contributors to the majority of the disease.  
The popular belief that Aβ initiates AD pathogenesis set off a plethora of anti-amyloid 
based treatments (Janus et al., 2000; Morgan et al., 2000; Schenk et al., 1999). So far targeting 
senile plaques in clinical trials has failed to stop or even conclusively slow disease progression 
(Aisen & Vellas, 2013; Mangialasche, Solomon, Winblad, Mecocci, & Kivipelto, 2010; Rinne et 
al., 2010). This implies amyloid deposition may represent a consequence, as opposed to cause, of 
the disease. A recent study of microbleed events associated with β-amyloid immunization has 
concluded that immunization actually facilitates cerebral microbleeds and worsens iron deposits 
in the choroid plexus (Joseph-Mathurin et al., 2013).  
In light of these failed treatments, new approaches are needed. This can likely be 
achieved through targeted manipulation of multiple pathways based on currently unidentified 
endophenotypes. In AD, mitochondria-associated endophenotypes have been considered due to 
the maternal inheritance associated with sporadic AD and correlative maternal mt-DNA 
inheritance (Swerdlow, 2011b). With enough evidence supporting a mitochondrial and metabolic 
role in disease, a novel approach to treatment strategy has been proposed. Termed ‘‘bioenergetic 
medicine’’, the rationale behind the approach involves the manipulation or support of those 
pathways that influence or are directly involved in bioenergetic flux (Swerdlow, 2013). This 
includes previously described mitochondrial medicine approaches in which mitochondria and 
mitochondrial regulated cellular processes are targeted. These approaches include manipulating 
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ETC components based on the functional state of mitochondria or cell energy status, influencing 
mitophagy events, changing mitochondrial mass, and even directing mitochondrial mediated 
apoptotic events (Swerdlow, 2011b). A recent study by Zhang et al demonstrated prevention of 
Aβ accumulation and protection against cognitive decline in triple transgenic AD mice by 
modulation of the mitochondrial ETC complex I using a novel compound known as CP2 ((Zhang 
et al., 2015). Targeting bioenergetic flux for treatment might be better understood in the context 
of AD pathology.  
During the early stages of AD, prior to mild cognitive impairment syndrome, β-amyloid 
deposition is abundant. It is not until after senile plaque formation drastically slows that the 
disease manifests. It has been suggested that the early deposition of senile plaques is coupled 
with a state of compensated metabolic function (Swerdlow et al., 2013). That is, compensation 
for dysfunctional metabolic processes is responsible for β-amyloid production in the events 
preceding cognitive impairment, representing a form of compensated brain aging. At the point at 
which the framework supporting these compensatory actions is stressed to fracture, metabolic 
processes are down regulated and hypometabolism sets in. At this stage, plaque deposition halts 
and uncompensated brain aging occurs, resulting in the onset of the clinical symptoms of 
Alzheimer’s disease (Figure 1.2).  
The notion of compensated vs. uncompensated states of dysfunction can also be applied 
to patterns in diabetes, with changes in metabolic flux, β-cell mass, and global metabolic 
regulation differing from prediabetes to clinical onset (Greenbaum, Buckingham, Chase, 
Krischer, & Diabetes Prevention Trial, 2011; Sysi-Aho et al., 2011; Tsai, Sherry, Palmer, & 
Herold, 2006; Yoneda et al., 2013) (Beck-Nielsen & Groop, 1994). In addition, pre-diabetic 
NCB5OR knockout mice show a marked increase in metabolic rate prior to the onset of diabetes 
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(Xu et al., 2011). It is possible, and even probable, that mechanisms similar to those responsible 
for compensated brain aging play a role in the events preceding the development of diabetes 
mellitus. Therefore, investigating pathways contributing to metabolic flux and dysfunction in 
both AD and diabetes will provide novel therapeutic insights. 
The mitochondrial cascade hypothesis has helped to provide a broad overarching 
perspective to evidence of altered brain bioenergetics and mitochondrial function in AD. 
However, identifying targets for therapeutic intervention is as complex as the disease itself. This 
is due, in part, to the infancy of risk estimation incorporating both familial history and genetic 
background in complex diseases (Aiyar et al., 2013). The identification of endophenotypes and 
eventually multiple and specific targets in complex diseases will require personalized approaches 
to treatment, complicating the issue further. In short, complex diseases will require complex 
treatment. So with the development of complex, personalized treatment on the seemingly distant 
horizon, progress toward effective therapy can likely be made through evaluating genetic 
networks in the context of the MIND paradigm. 
1.2 NADH Cytochrome b5 oxidoreductase 
1.2.1 NCB5OR; gene, protein, and function 
First cloned in 1999 by Dr. Hao Zhu, NADH cytochrome-b5-oxidoreductase (NCB5OR) is 
a highly conserved, ubiquitously expressed, soluble, heme-containing reductase associated with 
the endoplasmic reticulum (H. Zhu et al., 2004b; H. Zhu, Qiu, Yoon, Huang, & Bunn, 1999). 
The complete, functional isoform on which the majority of studies have been conducted is 
encoded by 16 exons located on chromosomes 6 and 9 in humans and mice, respectively. The 
protein contains a cytochrome b5 and b5 reductase domain, joined by a unique, HSP20 like 
linker region (Figure 1.3). While an exact function and pathway for NCB5OR has yet to be 
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determined, evidence suggests that the protein is a potent reductase of Fe and heme proteins (e.g. 
cytochrome c) in vitro and plays a significant role in the maintenance of iron homeostasis and 
pathways critical to proper metabolic and mitochondrial function (H. Zhu et al., 2004b; H. Zhu, 
Wang, W.F., Wang H.P., Xu, M., E, L., and Swerdlow, R.H., 2013). Since NCB5OR was shown 
to be associated with the endoplasmic reticulum, early studies aimed to clarify whether NCB5OR 
was involved in ER stress response pathways. Investigators concluded that while the NCB5OR 
promoter does respond positively to acute oxidative stress due to the presence of an anti-oxidant 
response element, overall it does not respond to the induction of ER stress or associated 
pathways and thus is not involved in the ER stress response (Larade & Bunn, 2006). In addition, 
the loss of NCB5OR results in increased respiration, oxidative stress, and fatty acid catabolism 
(Xu et al., 2011). Interestingly, it seems that while NCB5OR might respond to oxidative stress 
and plays no role in ER stress response pathways, loss of its function results in significant 
amounts of oxidative and ER stress. 
Due to the reductase activity and observed altered iron homeostasis with decreased levels of 
ferritin proteins (both heavy and light chains) in its absence, NCB5OR was proposed to facilitate 
management of the labile iron pool content and cellular iron storage by reducing ferritin heavy 
chain, a key component of cellular iron storage. However, recent experiments involving ferritin- 
caged iron demonstrated that addition of recombinant NCB5OR does not release stored iron by 
way of ferritin reduction in vitro
1
. 
1.2.2 NCB5OR and diabetes 
Transgenic mice globally deficient in NCB5OR (GKO mice) exhibit low body weight 
(beginning at 2 weeks of age), petite skeletal structure/build, lipoatrophy and impaired lipid 
storage, and develop early onset lean diabetes due to necrotic loss of insulin producing β-cells in 
                                                 
1
 Rivera and Zhu, unpublished data. 
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the endocrine pancreas (Larade et al., 2008; Xie et al., 2004; Xu et al., 2011). There is a 
definitive and pronounced difference of diabetes onset between male and females, with males 
displaying an onset of approximately 7 weeks of age and females delaying to as late as 20 weeks 
of age (Xie et al., 2004). The reason for this delay is unknown however it has been suggested 
that this might be due to the inherent differences in basal metabolic rates between males and 
females. Since NCB5OR was shown to be associated with the endoplasmic reticulum, early 
studies aimed to clarify whether NCB5OR was involved in ER stress response pathways. Β-cell 
injury in NCB5OR deficient mice is rapid and severe. Investigations into the cause of β cell 
injury revealed a large amount of oxidative stress along with significant ER distention and ER 
stress that differs from canonical pathway associated with the unfolded protein response (W. 
Wang et al., 2011).  
1.2.3 NCB5OR and mitochondria and iron.   
 Diabetes, oxidative stress, fatty acid catabolism, and even crosstalk with the endoplasmic 
reticulum all converge at a common medium: mitochondria.  During multiple studies 
mitochondrial function and morphology were assess in tissues lacking NCB5OR. Electron 
microscopy performed on pancreatic β-cells isolated from GKO mice revealed an increase in 
mitochondrial number and distended morphology with some evidence of electron dense granules 
present within the mitochondrial matrix, a finding commonly attributed to iron accumulation 
(Xie et al., 2004). These changes are possibly indicative of mitochondria undergoing a 
permeability transition which could trigger apoptosis; however assays evaluating apoptotic β-cell 
death were negative, indicating otherwise.   
Further studies utilized islet transplants (TKO mice) to further explore the systemic effects 
of NCB5OR deficiency without the confounding factors introduced by insulin deficient diabetes 
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(Larade et al., 2008). A primary observation made in these studies was that of continued 
lipoatrophy in the context of sufficient insulin production.  Further analysis resulted in evidence 
that NCB5OR plays a vital role in fatty acid desaturation, a process upstream of mitochondrial β-
oxidation. Microarray data derived from mRNA from TKO livers showed a marked increase in 
PGC-1α, a stimulator of mitochondrial biogenesis (Larade et al., 2008).  An investigation 
specifically targeting the effects of NCB5OR deficiency on mitochondria, fatty acid catabolism, 
and oxidative stress demonstrated an increased rate of mitochondria mediated fatty acid 
oxidation in KO hepatocytes, accompanying observations of increased mitochondrial 
proliferation and content in the liver of pre-diabetic GKO mice (Xu et al., 2011). Similar findings 
regarding mitochondrial proliferation and content were confirmed in β-cells (W. Wang et al., 
2011).   
 In order to better understand the totality of changes that loss of NCB5OR induces at the 
cellular level, microarrays and quantitative PCR of mRNA were conducted on GKO and WT 
islets from mice 5 weeks of age. A number of iron related genes, including genes involved in 
iron import and regulation, were significantly up regulated in GKO mice compared to WT, and 
changes in a few iron related genes were observed in new born mice. Further investigation into 
the status of iron in global and tissue specific, conditional KO mice revealed that GKO mice 
presented with mild to moderate anemia and general iron deficiency in iron rich tissues such as 
the spleen and liver. In fact, GKO mice subjected only to overnight fasting displayed a sharp 
decrease in circulating iron levels and transferrin saturation. During fasting states, the livers of 
WT mice displayed an 8-fold increase in Hamp1 expression while GKO mice displayed a 130-
fold increase in Hamp1 expression. Hamp1 is a key regulator of dietary iron absorption at the 
duodenum. Hepcidin, the protein for which Hamp1 codes, is a potent inhibitor of ferroportin, the 
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key transporter for dietary iron absorption in the duodenum and the sole transporter responsible 
for cellular iron export. Thus when hepcidin levels increase, iron absorption decreases. The drop 
in serum iron concentration coupled with the increase in hepcidin levels is consistent with 
previous observations made in WT mice during the fasting state. Experiments conducted using 
radioactive 
59
Fe revealed an interesting change in brain iron uptake. Initial iron assays of the 
brains of GKO mice displayed little to no iron deficiency. However, when GKO mice are fasted 
and undergo oral gavage with 
59
Fe a significant increase in uptake of circulating 
59
Fe is observed. 
The drastic response in GKO mice indicates an increased sensitivity to the fasting state and an 
overcompensation of iron regulatory elements due to NCB5OR deficiency.
2
   
Defects in mitochondrial function and iron metabolism may be at the heart of dysfunction 
in the context of NCB5OR deficiency.  ETC function, mitochondrial function, iron metabolism, 
and heme synthesis are processes that are reliant upon one another.  Since iron dyshomeostasis 
can alter proper mitochondrial function and vice versa, there exists a state of pseudo-quantum 
entanglement when addressing the onset of dysfunction due to NCB5OR deficiency.  This is 
important when considering the design of future studies aimed at understanding the effects of 
NBC5OR deficiency on specific systems, largely due to the existence of gene expression profiles 
that are unique for certain cell types and tissues.   
1.2.4 Preliminary behavior observations in NCB5OR deficiency 
Since the brain is metabolically demanding and heavily reliant upon proper iron 
homeostasis, observations of altered iron homeostasis and mitochondrial function led to early 
questions about the effects of NCB5OR deficiency on behavior. A preliminary behavioral 
experiment using a y-maze and force-plate actimetry showed that non-diabetic mice globally 
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deficient for NCB5OR are significantly hyperactive compared to WT counterparts (Figure 1.4)
3
.  
However, since mice globally deficient for NCB5OR have possible confounding factors such as 
altered metabolism and  mild to moderate anemia, further experimentation is needed to 
determine if behavioral changes observed in GKO mice are the result of primary or secondary 
dysfunction.  
1.3 The Cerebellum: A model system   
The cerebellum (or ‘little brain’) is a highly organized, distinct structure that houses up to 
50% of the total neurons in the brain. The cellular organization of the cerebellum is composed of 
three easily identifiable layers: the molecular layer, the Purkinje layer, and the granular layer 
(Figure 1.5). Beginning in the 19th century, the cerebellum was thought to solely modulate 
motor function and maintenance of posture, tonus, motor learning, balance, and coordination.  
However this view has been challenged over the past few decades with a broad range of 
behavioral, physiological, and anatomical evidence suggesting a role for the cerebellum in higher 
cognitive functions such as language, learning, social cognition, and emotional processes 
(D'Angelo et al., 2011; De Smet, Paquier, Verhoeven, & Marien, 2013; Hoche, Guell, Sherman, 
Vangel, & Schmahmann, 2015; Schmahmann, 2001). Major contributions to this contention have 
been made by Schmahmann et. al. who first described cerebellar cognitive affective syndrome in 
1997 (Schmahmann & Sherman, 1997, 1998). Investigations have revealed cerebellar damage 
and dysfunction to result in language or language associated deficits such as syntax impairment, 
verbal fluency, dyslexia/alexia, agraphia, apraxia, and aphasia (De Smet et al., 2013; Marien, van 
Dun, & Verhoeven, 2015).    
The cerebellum’s involvement in higher cognitive and emotional processes has sparked 
an interest in its involvement in those diseases in which related processes might be affected, 
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including AD. Traditionally the cerebellum’s involvement in the presentation and pathology of 
AD was ignored, likely due to lack of information regarding cerebellar function coupled with a 
strong pathological and histological presentation of abnormalities in other brain regions. 
However, in 1980 Pro. et al demonstrated the presence of amyloid plaques in a postmortem 
analysis of the cerebellum in what were then characterized as ‘pre-senile’ Alzheimer’s patients 
(Pro, Smith, & Sumi, 1980). In addition, articles published by separate groups during the 
Summer of 1989 reported the presence of amyloid plaques in the cerebellum of 52-80% of a 
population of pre-senile, senile, familial, and 21 trisomy associated AD patients (Brucher, 
Gillain, & Baron, 1989; Cole, Williams, Alldryck, & Singharo, 1989). Interestingly, another 
study screened over 600 peptides from the cerebellum of AD patients and found that 15 peptides 
were elevated, 9 of which were fragments of hemoglobin (Slemmon, Hughes, Campbell, & 
Flood, 1994). However, the presence of plaques in the cerebellum does not necessarily infer 
pathological consequences. Further investigation demonstrated significantly reduced volumes of 
the molecular (24%) and granular layers (22%) and a 32% reduction in the number of Purkinje 
cells from the cerebellums of 11 patients who had reached severe, end-stage AD (Wegiel et al., 
1999). Structural MRI has also demonstrated significantly smaller posterior cerebellar lobes and 
correlative lower cognitive performance in AD patients (Thomann et al., 2008). Even the 
standard practice of normalization using the cerebellum in perfusion studies has been called into 
question based on evidence of cerebellar changes in AD (Lacalle-Aurioles et al., 2013). Deficits 
in neuropsychological functions can be directly correlated to altered metabolism in the 
cerebellum of AD patients (Newberg et al., 2003) as well as a general reduction in cerebellar 
glucose metabolism in advanced AD (Ishii et al., 1997). 
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Finally, the expression of NCB5OR in the cerebellum has been confirmed by qPCR and a 
previous study which suggested NCB5OR’s importance in Bergmann glia function during 
development (Koirala & Corfas, 2010). Interestingly, NCB5OR expression correlates temporally 
with observed iron accumulation in Bergmann glia during early postnatal development (J. Y. 
Kim et al., 2014). These findings along with the unique structure, cognitive and motor influence, 
diverse and unique cell types, and distinct properties of the cerebellum make it an ideal model 
system for studying effects on a broad range of behaviors while maintaining focus on a simple 
and uniform molecular and anatomical environment. 
1.4 Statement of Hypothesis 
The etiology of many neurodegenerative diseases is still undetermined. In the absence of 
explanation and amidst a significant amount of data, it has been suggested that metabolism and 
metabolic pathways contribute significantly to the pathology of many neurodegenerative 
diseases. However the complex nature of these diseases makes identifying contributing genes, 
pathways, and processes extremely difficult. In order to address this issue we have begun 
exploring the notion of metabolic influence over complex neurodegenerative diseases by first 
considering those diseases that share incidence as well as common pathways and defects; 
specifically diabetes and pathways relating to mitochondria and iron. 
We aim to investigate how genes important for metabolic and iron related processes affect 
neural tissue, specifically in the cerebellum. One such gene, NCB5OR, is an oxidoreductase 
ubiquitously expressed in mammalian tissue (H. Zhu et al., 1999). A previous study found that 
during early postnatal development NCB5OR was one of a subset of genes whose expression 
increased 120-fold in Bergmann glia cells in the cerebellum (Koirala & Corfas, 2010). It is 
important to note that this increase in expression parallels previously observed iron deposition in 
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Bergmann glia beginning in early postnatal development. Interestingly, global ablation of 
NCB5OR results in monogenic diabetes as well as defects in mitochondria and iron related 
pathways and processes. To further investigate the influence of iron and metabolic homeostasis 
in the pathology of disease we are investigating the effects of NCB5OR deficiency on neural 
tissue and pathways in the cerebellum and midbrain. Our central hypothesis is that loss of 
NCB5OR in the mouse cerebellum and midbrain will alter tissue iron homeostasis and result in 
dysfunction in pathways and behaviors to which the cerebellum and midbrain contribute. This 
research was directed by three central aims. 
1. To characterize changes in iron homeostasis and locomotion associated with loss 
of NCB5OR in the mouse cerebellum and midbrain.  
2. To evaluate whether loss of NCB5OR in the cerebellum alters feeding behavior 
and metabolic homeostasis.  
3. To determine the effects of NCB5OR deficiency on 5HT, DA, GABA, and Glut 





























Table 1.1 Similarities between β-cells and neurons as described by Arntfield et. al (Arntfield & 




Figure 1.1 The MIND paradigm. Bioenergetic homeostasis lies at the nexus between common 
defects found in neurodegenerative disease and diabetes mellitus. Mitochondria and iron play a 
critical role in bioenergetic homeostasis, suggesting that disturbances in proper mitochondrial 







Figure 1.2 Bioenergetic homeostasis in disease.  A.) Visual representation of bioenergetic 
homeostasis, with the midline indicating an ideal flux/balance in bioenergetic pathways.  
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Distorted mitochondrial function and iron metabolism result in bioenergetic dysfunction, shifting 
away from ideal bioenergetic homeostasis.   B.) Graphical representation of compensated versus 
uncompensated states of bioenergetics in AD.  Ideally, bioenergetic homeostasis results in 
compensated aging and no plaque deposition.  However, in instances of bioenergetic dysfunction 
plaque deposition occurs during compensated brain aging. At the point at which compensatory 
mechanisms fail, plaque deposition slows or stops and disease manifests. Severe bioenergetic 




















Figure 1.3 Structure and domains of the NCB5OR gene and protein.  NCB5OR, also named 
Cyb5R4 (cytochrome b5 reductase 4), contains 3 homologous domains to protein-coding genes 
that exist separately in the genome.  The protein is composed of an N-terminal cytochrome b5 

















Figure 1.4 Preliminary observations of hyperactivity in female, non-diabetic GKO mice. (A&B) 
Force plate actimeter data reveals increased distance traveled and area measure in GKO mice. 
(C) GKO mice challenged with a y-maze experiment show significantly increased arm entries 
relative to WT mice, indicating increased exploratory locomotor activity in a confined space. 
Values are presented as mean +/- SEM (standard error of mean). n=5 WT  n=9 GKO at 10 weeks 





Figure 1.5 Organization of the cerebellum. (A) The cerebellum contains multiple folia 
(wrinkles) that contain 3 distinct functional layers: the outermost molecular layer (ml), the 
middle Purkinje cell layer (PCl), and the inner granular cell layer (gcl) where over 50% of the 
total neurons in the brain are located. The majority of communication to and from the cerebellum 
is mediated through the deep cerebellar nuclei (DCN).  (B) Confocal microscopy of TdTomato 
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labeled neurons and their axons projecting to the DCN. (C) The Purkinje cell (PC) is the primary 
source of output from the cortex to the DCN in the cerebellum and is surrounded by supporting 
cells known as Bergmann glia (BGC). (D) Detailed confocal microscopy of YFP labeled 
Purkinje cells. Note the complex dendritic arborization.  (A) and (C) were adapted from the 
publication “Connexin43 and Bergmann glial gap junctions in cerebellar function”. 
http://dx.doi.org/10.3389/neuro.01.038.2008. Image in (B) and (D) were collected by Stroh MA 
during preliminary experiments using tamoxifen induced neuron-specific YFP and cre 






























LOSS OF NCB5OR IN THE CEREBELLUM DISTURBS IRON PATHWAYS, 
POTENTIATES BEHAVIORAL ABNORMALITIES, AND EXACERBATES 















Iron dyshomeostasis has been implicated in many diseases, including a number of neurological 
conditions. Cytosolic NADH cytochrome b5 oxidoreductase (NCB5OR) is ubiquitously 
expressed in animal tissues and is capable of reducing ferric iron in vitro. We previously reported 
that global gene ablation of NCB5OR resulted in early-onset diabetes and altered iron 
homeostasis in mice.  To further investigate the specific effects of NCB5OR deficiency on neural 
tissue without contributions from known phenotypes, we generated a conditional knockout 
(CKO) mouse that lacks NCB5OR only in the cerebellum and midbrain. Assessment of 
molecular markers in the cerebellum of CKO mice revealed changes in pathways associated with 
cellular and mitochondrial iron homeostasis. 
59
Fe pulse-feeding experiments revealed 
cerebellum-specific increased or decreased uptake of iron by 7 weeks and 16 weeks of age, 
respectively. Additionally, we characterized behavioral changes associated with loss of 
NCB5OR in the cerebellum and midbrain in the context of dietary iron deprivation-evoked 
generalized iron deficiency. Locomotor activity was reduced and complex motor task execution 
was altered in CKO mice treated with an iron deficient diet.  A sucrose preference test revealed 
that the reward response was intact in CKO mice, but that iron deficient diet consumption altered 
sucrose preference in all mice. Detailed gait analysis revealed locomotor changes in CKO mice 
associated with dysfunctional proprioception and locomotor activation independent of dietary 
iron deficiency. Finally, we demonstrate that loss of NCB5OR in the cerebellum and midbrain 
exacerbated harmaline-induced tremor activity. Our findings suggest an essential role for 
NCB5OR in maintaining both iron homeostasis and the proper functioning of various locomotor 





Iron deficiency is the most prevalent nutrient deficiency worldwide (WHO, 2001).  Iron 
plays critical roles in a myriad of cellular pathways and processes, ranging from metabolism to 
gene transcription.  The importance of iron to cellular and systemic processes is evident when 
considering the wide variety of diseases either directly caused by or associated with iron 
dyshomeostasis (Fernandez-Real, McClain, & Manco, 2015).  Maintenance of brain iron 
homeostasis is relevant to several neurological diseases and the importance of iron in 
neurocognitive development has been established (D. G. Thomas, Grant, & Aubuchon-Endsley, 
2009). Alterations in brain-specific or global iron homeostasis have been directly observed or 
associated with neuropathological diseases like Alzheimer’s disease, Parkinson’s disease, and 
neurodegeneration with brain iron accumulation, as well as cognitive disorders including autism 
spectrum disorders, attention deficit hyperactivity disorder, schizophrenia, and many more 
(Belaidi & Bush, 2015; Insel, Schaefer, McKeague, Susser, & Brown, 2008; Konofal et al., 
2007; Zucca et al., 2015).  A number of studies have evaluated the effects of maternal, neonatal, 
and adolescent iron deficiency. Whether changes in iron content or homeostasis are a means or 
an ends has yet to be determined, thus pathways and processes that alter or contribute to iron 
homeostasis are critical in understanding the underlying etiology and pathology of a number of 
diseases. 
NCB5OR is a highly conserved, ubiquitously expressed oxidoreductase associated with 
the endoplasmic reticulum whose exact function remains unknown (H. Zhu et al., 2004b; H. Zhu 
et al., 1999). Naturally occurring polymorphism’s in human NCB5OR have been shown result in 
increased proteasomal degradation (Kalman et al., 2013). Transgenic mice globally deficient in 
NCB5OR (GKO) have low birth weight (beginning at 2 weeks of age), petite skeletal 
43 
 
structure/build, impaired lipid storage and lipoatrophy, hypermetabolism, mitochondrial 
dysfunction, and early-onset diabetes from necrotic β-cell loss when compared to normal or 
wildtype (WT) control mice (Larade et al., 2008; W. F. Wang et al., 2011; Xie et al., 2004; Xu et 
al., 2011). We recently discovered that global loss of NCB5OR results in mild to moderate 
anemia, significant changes in iron related pathways, and iron deficiency in iron rich tissues such 
as the spleen and liver (H. Zhu et al., 2013).  Further investigation using a radioactive pulse 
feeding assay combined with a non-heme iron assay revealed that the brains of GKO mice 
uptake significantly more circulating 
59
Fe compared to WT controls, despite showing no 
apparent change in non-heme iron content (see footnote 1).  
Changes in iron homeostasis, mitochondrial dysfunction, and diabetes and their 
correlation with neurodegenerative diseases (Stroh, Swerdlow, & Zhu, 2014) led us to ask what 
specific effects NCB5OR deficiency had on neural tissue. Ataxia with Oculomotor Apraxia 
(AOA2) and sideroblastic anemia with ataxia have been shown to be related to changes in iron 
homeostasis in the cerebellum.  Additionally, Friedreich’s ataxia results in mitochondrial iron 
dyshomeostasis, dorsal root ganglia degeneration, and atrophy of the dentate nuclei without 
changes in iron content (Solbach et al., 2014). Genes associated with these diseases are 
ubiquitously expressed; however alleles with mutations or expansions appear to have adverse 
effects on specific tissue types, namely neural tissue. A microarray study surveying changes in 
gene expression in Bergmann glia during the postnatal development of the mouse cerebellum 
revealed NCB5OR to be one of a few that were significantly up-regulated (~120 fold) beginning 
postnatal day 6 (Koirala & Corfas, 2010). This observation coincides with a sequential iron 
accumulation in chick Bergmann glia beginning postnatal day 2 as well as the localization of 
transferrin binding protein, ferritin, and iron in Bergmann glia (Cho, Shin, Lee, Hwang, & 
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Chang, 1998; J. Y. Kim et al., 2014). Loss of iron related genes in the cerebellum has been 
shown to alter locomotion and induce degeneration, ataxia, and developmental issues (Capoccia 
et al., 2015; LaVaute et al., 2001; Maccarinelli et al., 2015; Zhao, 2015). Additionally, cognate 
motor learning and execution of a complex motor task requires proper nigrostriatal function as 
well as efficient processing of proprioceptive input by the cerebellum (Salamone, 1992).  
Therefore, we investigated whether loss of NCB5OR in the cerebellum and midbrain would 
result in locomotor deficits and whether dietary iron deficiency would reveal or exacerbate any 
deficits.  
2.3 RESULTS 
2.3.1 Effective deletion of NCB5OR in the CKO cerebellum.  
Mice expressing the En-1 driven cre recombinase showed effective recombination of a 
TdTomato reporter allele in the cerebellum and mid-brain (Figure 2.1).  Quantitative PCR 
(qPCR) analysis of reverse transcribed mRNA with primers targeting exon 4, which is not 
deleted in CKO tissues, revealed a significantly reduced level of NCB5OR transcripts in the 
cerebellum of CKO mice relative to WT controls (CKO, 17.6±1.4; WT, 24.9±1.4; p=0.003, see 
table 1 for conditions).  In addition, qPCR  with primers targeting the floxed exon 3 revealed an 
absence of functional NCB5OR transcripts in CKO mice relative to WT controls (CKO, 
0.33±0.64; WT, 8.33±0.64; p<0.001). 
2.3.2 NCB5OR deficiency results in changes in iron related pathways and uptake of circulating 
59
Fe.  
To assess whether loss of NCB5OR in the cerebellum facilitated changes in iron related 
pathways we performed qRT-PCR analysis on mRNA isolated from the cerebellum of CKO 
mice and WT littermates (Table 2.1).  At 7 weeks of age, CKO mice displayed significantly 
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elevated transcripts for many genes associated with or responsible for proper maintenance of 
cellular and mitochondrial iron homeostasis.  Iron transport and import transcripts transferrin 
(Tf) and transferrin receptor (TfR1), respectively, were both significantly elevated. Interestingly, 
transcripts for the only known iron exporter ferroportin (Fpn1) were significantly increased.  
Transcripts of proteins responsible for iron storage (ferritin heavy chain, FtH, and ferritin light 
chain, FtL) were also found to be significantly elevated in CKO mice. Additionally, transcripts 
for amyloid precursor protein (APP) were elevated. APP has been shown to have ferroxidase 
activity and an iron-responsive element in the 5’ untranslated region of the transcript (Duce et 
al., 2010; Rogers et al., 2002). Mitochondria-associated iron transcripts frataxin (Fxn) and 
mitoferrin 2 (MitoFn2) were elevated at 7 weeks as well. By 16 weeks of age, the majority of 
transcripts returned to levels comparable to WT control mice. However, transcripts for iron 
regulatory protein 2 (Irp2) and metallothionein 2 (Mt2) were found to be elevated at 16 weeks.   
We also performed transcript analysis of cerebellar mRNA at 7 weeks of age after mice 
had been challenged for 4 weeks with an iron deficient diet for behavioral analysis (Table 2.2).  
Transcript levels from male CKO mice showed drastic increases for a number of genes compared 
to WT controls as well as chow fed controls. Conversely, female CKO mice showed significant 
decreases in transcripts compared to WT controls and their male counterparts. 
Maintenance of iron homeostasis is heavily reliant on both transcriptional and 
translational regulatory mechanisms.  To assess whether the transcript levels accurately reflected 
the status of TfR1, FtH, and APP protein levels we performed western blot analysis of total 
protein collected from the cerebellum of male CKO and WT mice at 7 weeks of age (Figure 2.2).  
Levels of TfR1 were significantly elevated (Figure 2.2A), while FtH levels were significantly 
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decreased (Figure 2.2B).  Although CKO mice had elevated APP levels, they did not reach 
statistical significance when compared to WT (Figure 2.2A).  
In order to evaluate whether the changes in iron-related pathways were indicative of 
actual changes in iron uptake we conducted an 
59
Fe pulse feeding assay on CKO and WT mice at 
7 and 16 weeks of age.  At 7 weeks of age, CKO mice had significantly greater 
59
Fe uptake in the 
cerebellum (Figure 2.3A - left), while uptake in control tissues remained unchanged (spleen - 
Figure 2.3B - left, and liver - data not shown).  Surprisingly, by 16 weeks CKO mice had 
significantly lower 
59
Fe uptake in the cerebellum (Figure 2.3A - right) and CKO males exhibited 
significantly less iron uptake in the spleen (Figure 2.3B - right). No recombination in the spleen 
was seen using PCR (data not shown).  There were no changes in liver 
59
Fe uptake at 16 weeks 
(data not shown).  We tested whether the change in uptake was an indication of altered iron 
reserves in the form of non-heme iron content; however, measurement of non-heme iron content 
of the cerebellum and spleen of CKO mice revealed no changes in the cerebellum (Figure 2.3C) 
or spleen (Figure 2.3D) at 7 or 16 weeks of age.  
2.3.3 NCB5OR deficiency results in less ferric iron staining in Purkinje cells.   
The altered state of 
59
Fe uptake combined with no observable difference in non-heme 
iron content at 16 weeks of age in CKO mice led us to question whether there was a shift in the 
ratio of free to stored iron content.  A shift of this nature would result in different amounts of free 
iron in the ferrous state (Fe
2+
) and stored iron in the ferric state (Fe
3+
).  In order to test this 
hypothesis we needed a test that would differentiate between the two oxidative states of iron.  
Therefore, we performed histological analysis of 16 week old male cerebellum sections 
combined with Perls’ Prussian blue iron staining, which uses ferrocyanide to specifically stain 
for ferric iron.  Perls iron staining in combination with DAB enhancer revealed distinct staining 
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in Purkinje cells of the cerebellum (Figure 2.4A).  Iron positive and negative Purkinje cell counts 
revealed that CKO mice possessed a significantly reduced number of iron-positive Purkinje cells 
when compared to WT counterparts (Figure 2.4B). Control sections treated with only DAB 
(enhancer) and Nissl (counterstain) in the absence of Perls’ iron stain revealed no positive 
staining, indicating iron-specific staining (data not shown). 
2.3.4 Iron deficiency alters execution of complex motor tasks in CKO mice.  
Based on the changes in iron uptake and related pathways, we hypothesized that loss of 
NCB5OR in the cerebellum and midbrain would result in locomotor defects. Additionally, we 
investigated whether generalized iron deficiency brought about by chronic dietary iron 
deprivation would exacerbate any underlying deficits. It is important to note that gross 
differences in body weight can contribute to significant changes in certain behavior measures.  
There were no body weight differences between CKO and WT mice in either the chow or low-
iron diet fed groups, but we did note a significant difference in body weight of all mice between 
the chow and low-iron-diet treated groups during ages 4-7 weeks (Figure 2.5A).  
While there were no apparent differences in performance of the beam walk task between 
chow-fed CKO and WT mice  (Figures 2.6A and 2.6B), CKO mice on an iron-deficient diet took 
significantly longer to traverse an elevated beam at weeks 1,2, and 4 of low-iron-diet treatment. 
(Figure 2.5B) CKO mice also committed an increased number of paw slips (Figure 2.5C) 
compared to WT mice at weeks 2 and 3 of low-iron-diet treatment. Additionally, Rota-rod tests 
revealed that 7 week old CKO mice treated with an iron deficient diet for 4 weeks had a 
decreased latency to fall compared to WT mice (Figure 2.5D), indicating a deficit in 
coordination. When we compared the dietary effects within genotypes, we observed that the 
increased number of slips during the coordinated motor task was the result of the genotype 
48 
 
differences between CKO and WT mice (Figure 2.7A and 2.7B). However, the increased beam 
traversal time in the low-iron diet group was due to a hyperactive response in WT mice 
compared to no response in CKO mice (Figures 2.7C and 2.7D). 
2.3.5 An iron-deficient diet decreases exploratory locomotor activity in CKO mice.  
The resistance to a low-iron-diet-induced hyperactive response in CKO mice led us to 
investigate whether CKO mice had differences in locomotor activity when fed a low-iron diet. 
Force-plate actimeter data revealed no differences between CKO and WT mice on a chow diet 
(Figures 2.8A-D), with the exception of a difference in total distance traveled and spatial statistic 
during the initial 3 week age time point. However, treatment with a low-iron diet resulted in 
significantly reduced locomotor activity in CKO mice, yielding reduced total distance traveled 
(Figure 2.8E) and area measure (Figure 2.8F) compared to WT mice after 1-3 weeks of dietary 
iron deprivation.  Spatial statistics also indicate that the reduced locomotor output correlated with 
lowered exploratory activity during weeks 1 and 2 of dietary iron deprivation, with CKO mice 
spending more time in one area, generating a higher spatial statistic (Figure 2.8G). It is possible 
that changes in total distance traveled and area measures are indicative of slower locomotion 
rather than reduced overall locomotor activity and exploratory behavior, however CKO mice 
displayed significantly more bouts of low mobility during weeks 1 and 2 of low-iron-diet 
treatment (Figure 2.8H), suggesting that they spent more time being immobile than their WT 
counterparts.   
2.3.6 CKO mice display changes in locomotion independent of dietary treatment. 
To our surprise, gait analyses revealed a number of significant changes in 7 week old 
CKO mouse locomotion that were present in both chow- and low-iron-fed mice that were 
ultimately unaffected by the dietary iron deficiency. Compared to WT mice, CKO mice had a 
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wider stance width (Figure 2.9B), decreased step angle (Figure 2.9C), and increased distance to 
fore limb-hind limb paw overlap (decreased occurrence of superimposed tracks; Figure 2.9D).  
Additionally, CKO mice displayed changes in the rate in which they reach full stance (increased 
max ∆A/∆T, rate of change of paw area over time; Figure 2.9F) as well as an increase in the 
amount of paw drag (Figure 2.9G) from the time of full stance to liftoff.  
In order to confirm locomotor changes independent of dietary treatment and assess 
whether age was in important factor we performed gait analysis on 16 week old CKO and WT 
mice fed a chow diet. Comparative gait analysis between 7 and 16 week old CKO mice revealed 
that CKO mice had significantly increased Max ∆A/∆T (Figure 2.10A), midline distance (Figure 
2.10B), and distance to paw overlap (Figure 2.10C) regardless of age. In addition, CKO mice had 
decreased swing duration (Figure 2.10D), however this significance was not seen when 
comparing dietary influence at 7 weeks of age (data not shown). 
2.3.7 Reward response remains intact in CKO mice.   
Upon analysis of locomotor activity and Rota-rod performance, it became apparent that 
the effects of an iron-deficient diet not only had negative effects on CKO mice, but the effects 
appeared to be opposite that of WT mice exposed to a low-iron diet when compared to the chow 
diet.  For example, CKO mice on a low-iron diet displayed decreased performance on the Rota-
rod task compared to CKO mice on chow, while Rota-rod performance was greater in WT mice 
on a low-iron diet compared to WT mice on chow.  The increased performance of the WT mice 
under iron-deficient conditions led us to question whether the ventral tegmental area (VTA) was 
affected in both WT and CKO mice on low-iron diets.  Lesions in the tail of the VTA have been 
reported to result in increased Rota-rod performance in rats (Bourdy et al., 2014) and deletion of 
the dopamine D2 receptors in the VTA results in increased cocaine-induced locomotion. 
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Moreover, loss of dopamine D2 receptors in the VTA results in increased motivation for sucrose 
(de Jong et al., 2015).  
Therefore, we used a sucrose preference test to determine whether the loss of NCB5OR 
and the low-iron diet altered behaviors associated with the VTA.  In both chow-fed and low-iron- 
diet treated groups there were no significant differences between 6 week old CKO and WT mice 
for sucrose preference based on net consumption over a 24 hour period (Figures 2.11A and 
2.11B).  Interestingly, when comparing all mice treated with either a low-iron or chow diet, mice 
treated with a low-iron diet showed a significant shift away from sucrose preference compared to 
those on a chow diet (Figure 2.11C).  This suggests that dietary iron deficiency alters the reward 
response such that there is less preference for sucrose without affecting total liquid consumption.  
2.3.8 NCB5OR ablation in the cerebellum exacerbates peak harmaline-induced tremor.  
Since CKO mice did not show signs of gait asymmetry or overt ataxia like those seen in 
mice with cerebellar or dorsal root ganglia lesion or degeneration, we hypothesized that 
pathways responsible for rhythmic, central pattern generation as well as gross limb movement 
were being affected by loss of NCB5OR in the cerebellum.  These include the cerebelloreticular 
and cerebellorubral tracts (Figure 2.11D).  In order to test these, we investigated subcutaneous 
harmaline tremor response, a commonly known pharmacological method of induced 
essential/cerebellar tremor that utilizes the suspect afferent and efferent pathways. Twenty-four 
(24) week old CKO and WT mice were placed in an actimeter that allowed for spectral analysis 
of power for vertical forces between 0-25 Hz (Figure 2.11E).  Motion power percentages (MPP) 
for initial baseline session readings revealed no differences between CKO and WT mice. MPP’s 
for the initial onset of tremor activity (10 minutes post injection) in the 10-17 Hz range did not 
differ between CKO and WT mice. By 20 minutes post injection, CKO mice exhibited 
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significantly greater MPP’s than WT mice (Figure 2.11F).  The significant difference continued 
through 30 minutes post injection.  
2.4 DISCUSSION AND SUMMARY 
 Our study aimed to characterize iron-related and behavioral effects due to absence of a 
reductase, NCB5OR, in the mouse cerebellum and midbrain. To avoid complications of 
previously described phenotypes and changes associated with global loss of NCB5OR, we 
generated a cerebellum/midbrain specific conditional knockout (CKO) mouse. Strategic ablation 
of NCB5OR in the cerebellum and the midbrain allowed us to investigate the specific molecular 
effects of NCB5OR deficiency on neural tissue as well as evaluate changes in locomotive 
behavior due to loss of NCB5OR in areas known to affect locomotion. We demonstrated that 
ablation of NCB5OR in the cerebellum resulted in altered profiles of gene transcripts and 
proteins critical to iron metabolism and proper maintenance of cellular iron homeostasis.  
Normally, pathways responsible for iron uptake and export respond in accordance with cellular 
iron status.  During times of iron sufficiency, import and export of iron are regulated such that 
there is not significant uptake or release of iron, since cytosolic iron stores should compensate 
for any immediate increase in demand.  However, in times of iron deficiency, export is inhibited 
and uptake is increased, allowing for the accumulation of more iron without significant loss. In 
our model, loss of NCB5OR resulted in an abnormal response to normal iron bioavailability.  At 
7 weeks of age, neural tissue devoid of NCB5OR simultaneously acquired and exported 
available iron, consistent with observed changes in iron uptake (Tf and TfR) and export-related 
transcripts (Fpn1, APP, CP). Nutritional iron deficiency helped confirm our initial observations 
and led to interesting observations regarding sexual dimorphism in the iron-deprivation response. 
However, at 16 weeks no differences in levels of these transcripts were observed while less iron 
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was acquired by NCB5OR deficient tissue. It is important to note that we did observe elevated 
IRP2 and MT2 transcripts in 16 week old CKO mouse cerebellum.  IRP2 is a regulator of iron-
related transcript translation and therefore plays an important role in the abundance of proteins 
directly responsible for iron homeostatic maintenance (B. Guo, Yu, & Leibold, 1994; 
Samaniego, Chin, Iwai, Rouault, & Klausner, 1994). Levels of IRP2 protein are inversely 
correlated with iron content and are therefore increased in iron-depleted cells (Iwai, Klausner, & 
Rouault, 1995). Increased IRP2 transcript levels could indicate a shift from a transcriptional to a 
protein regulatory response to NCB5OR deficiency. MT2 also plays a role in metal homeostasis 
by regulating everything from heavy metal scavenging to zinc (Zn) acquisition and signaling. A 
role for Zn and metallothionein’s in autism spectrum disorders has been of growing interest 
(Russo, 2009; Vela et al., 2015).  Faber et al reported that the Zn/Cu ratio in children with autism 
spectrum disorder’s was abnormally low, suggesting alterations in metallothionein related 
pathways (Faber, Zinn, Kern, & Kingston, 2009).  
  The stark contrast in transcript and iron uptake response to NCB5OR deficiency at 7 and 
16 weeks of age may indicate a pattern of compensatory response and a subsequent compensated 
state, respectively. That is to say that by 16 weeks the loss of NCB5OR led to a shift in major 
iron homeostatic pathways as well as pathways dependent on iron. This resulted in the 
establishment of new homeostatic criteria, negating a need for a compensatory cellular response. 
This suggests not only an abnormal iron homeostatic response, but also abnormal iron flux, 
sensing, and pathway crosstalk. We used spleen and liver 
59
Fe levels as positive and negative 
controls, respectively, during our uptake experiments due to previous findings showing 
significantly elevated 
59
Fe uptake in the spleen and unchanged uptake in the liver of NCB5OR 





in either the spleen or the liver. However, at 16 weeks we were surprised to find significantly 
decreased uptake in the spleens of male CKO mice. PCR confirmed no loss of NCB5OR in the 
spleen (data not shown).  Direct communication and regulation from brain to the spleen 
moderated by cholinergic innervation has been identified and may contribute to this observation, 
and there is significant evidence demonstrating the existence of ‘brain-spleen inflammatory 
coupling’ (For review see (Rasouli, Lekhraj, Ozbalik, Lalezari, & Casper, 2011)). Histological 
analysis of iron staining in the cerebellum revealed further evidence of an altered homeostatic 
state in 16-week-old CKO mice.  The results, along with the observation of no alteration in total 
non-heme iron content, suggest that CKO mice may possess altered homeostatic criteria that 
allow for more ferrous (labile) iron. The latter is known to potentiate oxidative stress via the 
classical Fenton reaction mechanism. 
Brain iron homeostasis has been the focus of numerous studies, especially those focusing 
on the effects of neonatal/adolescent iron deficiency.  In fact, iron deficiency, dietary or 
otherwise, has been linked to a number of neurological and psychiatric conditions including 
restless leg syndrome and attention deficit hyperactivity disorder (Capoccia et al., 2015; Connor 
et al., 2003; Earley, Connor, Beard, Clardy, & Allen, 2005; Konofal et al., 2007; Konofal, 
Lecendreux, Arnulf, & Mouren, 2004; Konofal et al., 2008; Maccarinelli et al., 2015; Percinel, 
Yazici, & Ustundag, 2015; Provini & Chiaro, 2015; Qu et al., 2007). An investigation into the 
effects of iron deficiency and iron deficiency anemia in young Zanzibari children demonstrated 
lower motor activity scores and less time in locomotion in affected children (Olney et al., 2007).  
However, there is evidence that early dietary iron deficiency can result in either reduced or 
increased locomotion (Bourque, Iqbal, Reynolds, Adams, & Nakatsu, 2008; Fiset, Rioux, 
Surette, & Fiset, 2015). Targeted deletion of NCB5OR in the cerebellum and midbrain in the 
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present study did not result in overt changes in locomotion or coordination when mice were fed a 
chow diet with sufficient iron content.  However, NCB5OR deficiency combined with dietary 
iron deficiency significantly altered locomotion and coordination. Interestingly, when compared 
to chow fed controls, the effects of dietary iron deficiency appeared to be opposite for CKO and 
WT mice, with CKO mice becoming hypoactive (or unaffected, as seen in the beam walk time to 
traverse) and WT mice becoming hyperactive. Given that multiple studies have reported 
opposing effects of dietary iron deficiency on locomotion, it is interesting to note that ablation of 
NCB5OR in the cerebellum and midbrain resulted in a resistant or hypoactive response to iron 
deficiency while WT counterparts responded in a hyperactive manner.  Additionally, CKO mice 
fed an iron-deficient diet displayed decreased coordination and movement execution during 
complex motor tasks.  These changes indicate possible detrimental effects of NCB5OR 
deficiency on nigrostriatal pathways in the context of dietary iron deficiency. Genetic variations 
resulting in altered iron content in ventral midbrain nuclei have been linked to changes in 
locomotor activity (Unger, Sterling, Jones, & Beard, 2008). Also, interactions between iron, 
dopamine, and neuromelanin-related pathways have been indicated in Parkinson’s disease 
(Zucca et al., 2015).   
Changes in gait and ataxia are commonly associated with dysfunction in the cerebellum 
or proprioceptive pathways (Miyajima et al., 2001). However CKO mice did not display overt 
changes in gait symmetry or exhibit progressive ataxia (as is common with cerebellar lesion, 
degeneration, or altered proprioceptive input) compared to WT controls. Additionally, when 
compared to WT controls, CKO mice did not display changes in fore limb or whole body grip 
strength (data not shown), ruling out confounding factors of muscle weakness.  It is important to 
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note that while there were no genotype differences in the chow and low-iron diet groups, the 
low-iron diet did induce a mildly ataxic phenotype in all mice. 
The VTA contributes both to reward response and locomotor integration in reward-
associated tasks. Since CKO mice exhibited locomotor effects opposite those of WT mice when 
treated with a low-iron diet, we evaluated whether CKO mice in the low-iron diet treated group 
harbored changes in reward response compared to WT mice. Results indicate that reward 
response was intact in CKO mice and was comparable to that of WT mice in both chow and low-
iron diet groups. This suggests that the diet-dependent effects of NCB5OR deficiency are likely 
not originating from the VTA or VTA control over substantia nigral pathways. However, a low-
iron diet significantly reduced sucrose preference in all mice, indicating that iron dyshomeostasis 
or deficiency does alter reward response in mice.  Dopaminergic neurons in the VTA are thought 
to be the largest contributors to VTA mediated reward response.  Since we suspect that 
dopaminergic pathways in the substantia nigra are at the root of the diet dependent effects of 
NCB5OR ablation, the lack of genotype-diet interaction in VTA-dopaminergic-neuron- mediated 
behavior might indicate genetic susceptibility of certain dopaminergic neuron populations over 
others.  
We observed a number of changes in CKO mouse locomotion that were independent of 
and unaffected by dietary iron deficiency, suggesting that regions outside of the nigrostriatal and 
mesolimbic pathways may be affected. Gait analyses revealed that CKO mice had gait alterations 
indicating altered proprioception and central pattern-generated locomotion, resulting in 
hypometric hindlimb movements. In addition, these changes were found to occur in chow fed 
CKO mice regardless of age, confirming previous observations. However, the absence of ataxia 
and gait asymmetry in CKO mice suggests that changes may be due to physiological rather than 
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pathological mechanisms. We suspected the origins of diet-independent changes to be of lower, 
non-cognate motor task-associated pathways. We investigated whether pathways responsible for 
central pattern-generated locomotion (reticulospinal, rubrospinal, and associated tracts) were 
being affected by altered cerebellar input by using a harmaline-induced tremor assay. Harmaline 
treatment results in rhythmic burst firing in the medial accessory olive (MAO) and dorsal 
accessory olive (DAO) nuclei that excites vermis and paravermis Purkinje cells in the 
cerebellum.  The Purkinje cells project to the deep cerebellar nuclei (fastigial and interposed 
nuclei). Climbing fibers from the MAO and DAO also directly project to deep cerebellar nuclei. 
The deep cerebellar nuclei stimulate reticulospinal and rubrospinal fibers which play a role in 
control of posture, locomotion, and central pattern generation of locomotion (F. C. Martin, Le, & 
Handforth, 2005; Mori et al., 1998). At the cellular level, harmaline administration results in 
increased intraneuronal Ca
2+
 spikes in oscillating olivary neurons, leading to greater excitability 
(F. C. Martin et al., 2005).   The increased response to harmaline tremor in CKO mice could 






) homeostatic maintenance pathways in 
the absence of NCB5OR. Increased serotonin has also been shown to potentiate a greater 
response to harmaline-induced tremor.  These are important considerations when exploring 
further explanation of the changes seen in CKO mice. 
 In summary, our study has shown that genetic alterations leading to iron dyshomeostasis 
can affect a range of movement-related neural pathways, especially when combined with 
environmental factors such as generalized iron deficiency. These data suggest that NCB5OR 
deficiency results in alterations in iron homeostasis, but do not prove that NCB5OR directly 
contributes to iron homeostasis.  Although further experimentation is needed to address the 
latter, our current findings show that NCB5OR related iron dyshomeostasis, and pathways and 
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processes affected by iron, is of significance to the proper functioning of multiple neural 
















































Figure 2.1 EN-1 Cre driven recombination in the mouse brain. TdTomato reporter shows 
recombination in CKO mice. (A) Cerebellum, (B) Cerebellum and midbrain at 4
th
 ventricle, (C) 








Table 2.1 Transcript levels of genes involved in iron metabolism and homeostatic maintenance 
in the cerebellum of CKO and WT mice.  Transcript levels were determined by defining the 
internal reference, 18S rRNA, as 10
6
.  APP, amyloid precursor protein; Cp-GPI, GPI linked 
cerruloplasmin; Dmt1, divalent metal transporter 1; Fpn1, ferroportin; FtH, ferritin heavy chain; 
FtL, ferritin light chain; Fxn, frataxin; Hmox, heme oxygenase; Irp2, iron regulatory protein 2, 
MitoFn2, mitoferrin 2; MT2, metallothionein 2; MT3, metallothionein 3; TF, transferrin; TfR1, 
Transferrin receptor 1. Values are presented as mean +/- SEM (standard error of mean). n=8 WT 
(4 Male, 4 Female) and n=8 CKO (5 Male, 3 Female) at 7 weeks. n=8 WT (4 Male, 4 Female) 















Table 2.2 Transcript levels of genes involved in iron metabolism and homeostatic maintenance 
in the cerebellum of 7 week old CKO and WT mice fed either a chow or low-iron diet.  
Transcript levels were determined by defining the internal reference, 18S rRNA, as 10
6
.  APP, 
amyloid precursor protein; Cp-GPI, GPI linked cerruloplasmin; Dmt1, divalent metal transporter 
1; Fpn1, ferroportin; FtH, ferritin heavy chain; FtL, ferritin light chain; Fxn, frataxin; MitoFn2, 
mitoferrin 2; MT2, metallothionein 2; MT3, metallothionein 3; TF, transferrin; Tfr1, Transferrin 
receptor 1. Values are presented as mean +/- SEM (standard error of mean). n=8 WT (4 Male, 4 
Female) and n=8 CKO (5 Male, 3 Female) at 7 weeks for chow and low-iron diet treated. *, 











Figure 2.2 Iron-processing-relevant protein levels in the cerebellum of CKO and WT mice. 
Specific protein levels were measured using western blot analysis of whole protein extracted 
from mouse cerebellum at 7 weeks of age. (A)  Amyloid precursor protein (APP) was unchanged 
in CKO mice, but levels of the iron import protein transferrin receptor (TfR1) were significantly 
elevated. (B) Iron storage protein ferritin heavy chain (FtH) was significantly reduced in CKO 
mice, suggesting an iron-deficient status. Values are presented as mean +/- SEM (standard error 
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Figure 2.3 Altered iron uptake in CKO mice. 
59
Fe pulse feeding assay revealed (A) significantly 
elevated 
59
Fe uptake in the cerebellum of 7 week old CKO mice and significantly decreased 
uptake by 16 weeks of age. (B) Serving as a control, at 7 weeks the spleen showed no change in 
iron uptake. 16 week male CKO mice acquired significantly less 
59
Fe. Non-heme iron content 
assays of the (C) cerebellum and (D) spleen from 7 and 16 week old CKO and WT mice showed 
no changes in non-heme iron content. Values are presented as mean +/- SEM (standard error of 
mean). 7 week; n=10 CKO (5 Male, 5 Female), n=10 WT (5 Male, 5 Female). 16 week; n=10 












Figure 2.4 Reduced iron-positive Purkinje cells in male CKO mice. (Left) Perls iron staining in 
the CKO cerebellum with Nissl counterstaining. Note the positive staining (red arrows) and 
negative staining (black arrow) of purkinje cells. (Right) CKO mice have a reduced number of 
iron-positive Purkinje cells as a percentage of total Purkinje cells counted. Values are presented 
as mean +/- SEM (standard error of mean). Male mouse n=8 (4 CKO, 4 WT), sections used for 












Figure 2.5 Diet-dependent effects of NCB5OR deficiency during a complex motor task. (A) 
There were no genotypic differences in weight within chow or low-iron-diet treated sets, 
however low-iron-diet treated animals weighed significantly less than the chow fed controls. 
CKO mice on a low iron diet challenged with a complex motor task (elevated beam walk) 
showed (B) increased beam traversal time accompanied by (C) increased slips/errors during 
traversal. Dietary iron deficiency also resulted in (D) a decreased latency to fall on an 
accelerating Rota-rod task. Values are presented as mean +/- SEM (standard error of mean). 




Figure 2.6 Chow and low-iron diet effects on beam walk task. On a chow diet, no difference 
between WT and CKO mice was seen in (A) the number of slips/errors or (B) time to traverse.  
However, CKO mice fed a low-iron diet showed (C) an increased number of slips/errors and (D) 
a significant difference in beam traversal time when compared to WT controls fed a low-iron 
diet. Values are presented as mean +/- SEM (standard error of mean). Chow; n=8:10 (CKO:WT). 




Figure 2.7 Comparison of dietary effects on genotype. (A) WT mice and (B) CKO mice made 
significantly more slips/errors on the beam walk as a result of dietary iron deficiency.  However, 
dietary iron deficiency only affected the time to traverse in (C) WT mice, which showed a 
hyperactive response to the treatment. (D) CKO mice did not display the hyperactive response to 
the low-iron diet, suggesting resistance to the low iron diet impact. Values are presented as 
means +/- SEM (standard error of mean). Chow; n=8:10 (CKO:WT). Low iron; n=8:8 






 Figure 2.8 Diet-dependent effects of NCB5OR deficiency on locomotion.  Distance traveled, 
area measure, bouts of low mobility, and spatial statistic for mice fed a (A-D) chow diet or (E-H) 
low-iron diet. CKO mice on an iron-deficient diet had decreased total locomotor activity as 
indicated by (E) significant decreases in distance traveled and (F) area measure. CKO mice also 
exhibit reduced exploratory activity resulting in (G) high spatial statistics and (H) an increased 
number of low mobility bouts compared to WT. Spatial statistic scores: 100 = All time spent in 
one place, 1 = time spent evenly distributed across force plate. Bout of low mobility: 1 bout of 
low mobility = no change in distance or area (no movement) within a 10 second frame. Values 
are presented as means +/- SEM (standard error of mean). Chow; n=8:10 (CKO:WT). Low iron; 








Figure 2.9 Diet-independent effects of NCB5OR deficiency on gait. (A) Posture plots of WT 
and CKO mice at 7 weeks.  DigiGait analysis at 7 weeks revealed that CKO mice had (B) a 
wider stance width, (C) decreased step angle, and (D) a greater distance to paw overlap 
compared to WT mice.  (E) A visual representation of change in paw area over time. CKO mice 
show significant changes indicative of hind limb paresis with increased (F) max ∆A/∆T and (G) 
paw drag.   Max ∆A/∆T is the rate of change of paw area during paw placement and full stance.  
Paw drag is the paw area under the curve from full stance to liftoff.  CKO mice were quick to 
load their paw and spent more time initiating the liftoff stage (flopping and dragging their paws). 



















Figure 2.10 Age comparison of hind paw gait metrics in chow-fed CKO mice. (A) Similar 
trends in ∆A/∆T were seen between 7 and 16 week old CKO mice.  (B) Hind paws of CKO mice 
have an increased distance to the midline (transverse) regardless of age. (C) A greater distance to 
fore- paw-hind-paw overlap in 7 and 16 week old CKO mice. (D) CKO mice have a decreased 
swing duration at both 7 and 16 weeks of age. Values are presented as means +/- SEM (standard 
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error of mean). 7 week; n=8:10 (CKO:WT). 16 week; n=10:10 (CKO:WT). *, p<0.05; **, 
















Figure 2.11 Intact reward response and increased peak harmaline tremor in CKO mice.  Sucrose 
preference testing for CKO and WT mice fed a (A) chow diet and (B) low-iron diet. (C) A 
reduction in sucrose preference is seen when comparing the effects of a low-iron diet on all mice, 
suggesting that generalized iron deficiency significantly alters reward behavior in mice. (D) 
Treatment with subcutaneous harmaline results in rhythmic burst firing in the inferior olive and 
subsequent activation of rubrospinal and reticulospinal tracts via cerebellar efferents, generating 
a high frequency tremor. (E) Actimeter signals show a power spike in the 10-17 Hz range, 
indicative of a high frequency tremor. (F) CKO and WT mice had comparable motion power 
percentages (MPP) in the 10-17 Hz range during baseline and harmaline tremor onset (10 
minutes post injection). However, by 20 and 30 minutes post injection CKO mice had 
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significantly elevated responses to harmaline-induced tremor over WT. Values are presented as 
mean +/- SEM (standard error of mean).  DCN; deep cerebellar nuclei. IO; inferior olive. PC; 
Purkinje cell. RF; reticular formation. RN; red nucleus. For figures A-C: Chow; n=8:10 
(CKO:WT). Low iron; n= 8:8 (CKO:WT). For figure F: n=10:10 (CKO:WT). *, p<0.05; ***, 





























NCB5OR DEFICIENCY IN THE CEREBELLUM AND MIDBRAIN AFFECTS FASTED 













Cytosolic NADH cytochrome b5 oxidoreductase (Ncb5or) is ubiquitously expressed in 
animal tissues. We have previously reported that global ablation of NCB5OR in mice results in 
early-onset lean diabetes with decreased serum leptin levels and increased metabolic and feeding 
activities. The conditional deletion of NCB5OR in the mouse cerebellum and midbrain (CKO 
mice) results in local iron dyshomeostasis and altered locomotor activity. It has been established 
that lesion to or removal of the cerebellum leads to changes in nutrient organization, visceral 
response, feeding behavior, and body weight, likely due to alterations in cerebellar-hypothalamic 
circuitry.  This study assessed whether loss of NCB5OR in the cerebellum and midbrain altered 
feeding or metabolic activity and had an effect on serum T3, cortisol, prolactin, and leptin levels. 
Metabolic cage data revealed that 16-week-old male CKO mice had elevated respiratory 
quotients and decreased respiratory water expulsion, decreased voluntary exercise, and altered 
feeding and drinking behavior compared to wild-type littermate controls. Most notably, male and 
female CKO mice displayed over and under-consumption of food during refeeding after an 
overnight fast, respectively. Echo MRI revealed normal body composition but decreased total 
water content and hydration ratios in CKO mice. Serum leptin levels were significantly elevated 
in male CKO mice while prolactin, T3, and cortisol levels remain unchanged relative to WT 
controls. Taken together, these findings suggest potential alterations and dysfunction in 
cerebellar-hypothalamic circuitry as a result of NCB5OR deficiency. Further investigation is 
underway to elucidate the nature of changes resulting from NCB5OR deficiency in the 






Metabolism arguably lies at the core of cellular function, with many pathways 
contributing to its regulation and virtually all pathways reliant upon sufficient energy production 
and availability. Thus changes in pathways influencing metabolism have the potential to severely 
impact a cell’s vitality, function, and survival.  Neurodegenerative diseases and diabetes mellitus 
are two clinically distinct disease classes that share common defects in metabolic influence (for 
review, see (Stroh et al., 2014)). Changes in bioenergetic homeostasis, influenced largely by 
mitochondrial and iron related pathways, lie at the nexus of these conditions.  
NADH-Cytochrome-b5-oxidoreductase (NCB5OR) is a ubiquitously expressed, soluble, 
heme containing reductase associated with the endoplasmic reticulum (H. Zhu et al., 2004a; H. 
Zhu et al., 1999). Recently, naturally occurring non-synonymous mutations that lead to enhanced 
proteasomal degradation of NCB5OR have been identified in the human population (Kalman et 
al., 2013). To date, an exact function and pathway for NCB5OR has yet to be determined, 
however it is a potent reductase of iron and heme proteins (e.g. cytochrome c) in vitro and 
evidence suggests it plays a role in the maintenance of iron homeostasis and pathways critical to 
proper metabolic and mitochondrial function (H. Zhu et al., 2004a; H. Zhu, Wang, W.F., Wang 
H.P., Xu, M., E, L., and Swerdlow, R.H., 2013). Mice globally deficient for NCB5OR 
experience early-onset diabetes, growth retardation, decreased serum leptin levels, and increased 
food consumption despite maintaining a significantly reduced body weight relative to WT 
littermates (Y. Guo et al., 2012; Larade et al., 2008; Xie et al., 2004; Xu et al., 2011). We 
recently reported altered iron homeostasis, decreased iron-positive Purkinje cells, locomotor 
activity, and an increased response to harmaline-induced tremor in mice lacking NCB5OR in the 
cerebellum and the midbrain (CKO mice) (see footnote 1).  
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There exists a bidirectional network between the cerebellum and the hypothalamus (the 
cerebellar-hypothalamic circuit) that is known to play a role in circadian food anticipatory 
behavior, glucose sensing, satiety, metabolism, nutrient organization, thirst response, and body 
weight ((Mendoza, Pevet, Felder-Schmittbuhl, Bailly, & Challet, 2010), for review see (J. N. 
Zhu & Wang, 2008)). Therefore, we hypothesized that selective loss of NCB5OR in neural tissue 
would alter systemic metabolism, feeding/drinking behavior, and body weight. Through 
metabolic cage and biochemical analyses, we observed that CKO mice display significant 
changes in fasted feeding and ad libitum drinking behavior, fluctuation of body weight in 
response to overnight fasting, metabolic substrate utilization, and voluntary exercise with 
increases in serum leptin levels. These findings suggest potential alterations and dysfunction in 
cerebellar-hypothalamic circuitry as a result of NCB5OR deficiency in cerebellum and midbrain. 
3.3 RESULTS 
3.3.1 CKO mice had normal body weight and composition but less total and free water.  
Body weights were collected and averaged for light and dark cycles during individual 
housing in the metabolic cage system.  There were no discernable differences in body weight 
between CKO (light: 28.93±1.04 g, dark: 29.04±1.03 g) and WT mice (light: 31.62±1.04 g, dark: 
31.27±1.03 g) in either the light or dark cycles.  After metabolic cage experiments were 
concluded, body composition was assessed by measuring lean and fat mass via echo MRI.  There 
were no differences in lean or fat mass between CKO (lean: 24.13±0.81 g, fat: 2.65±0.37 g) and 
WT mice (lean: 25.77±0.77 g, fat: 2.87±0.32 g), but CKO mice had significantly less total water 
(Figure 3.1A) and no changes in free water (Figure 3.1B) relative to WT controls. Hydration 
ratios calculated from Echo MRI data revealed that CKO mice had significantly reduced 
hydration ratios compared to WT controls (Figure 3.1C). However, these results were driven by 
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significantly reduced hydration ratios in male CKO mice while female CKO hydration ratios 
remained unchanged relative to WT controls.  
3.3.2 Male CKO mice had decreased voluntary exercise and average energy expenditure.   
Mice were allowed access to a running wheel for the entirety of their housing in the 
metabolic cage system.  Both CKO and WT mice predictably traveled significantly greater 
distances on the running wheel during dark cycles compared to light cycles, indicating no strain 
differences in diurnal exercise trends (Figure 3.2A). However, this pattern was less clear when 
assessing strictly pedestrian locomotion (Figure 3.2B). While there were no apparent changes in 
diurnal trends, CKO mice exercised significantly less during the dark cycle compared to WT 
controls, with male CKO mice specifically showing a significant difference (Figure 3.2E). This 
change was not observed in pedestrian locomotion during the light or dark cycle or in exercise 
during the light cycle (Figures 3.2C, D, F). Note that the decreases in vO2 and total energy 
expenditure in male CKO mice were observed only during the dark cycle when male CKO mice 
were also observed to have participated significantly less in voluntary exercise. In addition, CKO 
mice did not present with abnormalities in gait symmetry (Figure 3.3A) or Rota-rod performance 
(Figure 3.3B), indicating no overt ataxia. 
 The rate of oxygen consumption (vO2) was used as an indicator to measure metabolic 
rate and total energy expenditure in CKO and WT mice (Figure 3.4).  Although vO2 were 
unchanged between CKO and WT mice during the light cycle (Figure 3.4A, C, E), a period when 
there is reduced activity and wheel running, we observed a marked decrease in vO2 and energy 
expenditure in male CKO mice compared to WT controls during the dark cycle (Figure 3.4B, D), 
a period of time when mice are more active and perform more wheel running. However, resting 
energy expenditure was not different between male CKO and WT mice (Figure 3.4F), suggesting 
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that vO2/energy expenditure differences were due to lower activity/wheel running in the CKO 
mice. Pearson correlation analysis revealed strong correlations between wheel activity and 
energy expenditure (0.77, p=0.006) and wheel activity and vO2 (0.79, p=0.004). 
3.3.3 Male CKO mice exhibited altered metabolic substrate preference, respiratory water 
expulsion, and water consumption behavior.  
Using indirect calorimetry we explored a number of metrics that are indicative of the 
metabolic state of the mice being observed.  Average respiratory quotients (RQ) (Figure 3.5A) of 
male CKO mice were significantly elevated during both the light (Figure 3.5B, top) and dark 
cycles (Figure 3.5C, top), indicating a greater reliance on carbohydrate utilization compared to 
WT controls. Elevated resting RQ values in male CKO mice during both the light (Figure 3.5B, 
bottom) and dark (Figure 3.5C, bottom) cycles confirmed the conditional independence of this 
observation.  
An increased RQ is indicative of a metabolic preference for glucose utilization. Since the 
brain uses glucose as its primary metabolic substrate, we asked whether the cerebellum in CKO 
mice was hypermetabolic, resulting in an increase in uptake and utilization of glucose.   In order 
to test this hypothesis in a simple manner we assessed whether there were changes in glucose 
uptake and key mRNA transcripts associated with brain glucose uptake and metabolism in the 
CKO cerebellum. We did not observe increased 2-deoxyglucose (2-DoG) uptake in CKO mice 
relative to WT controls (Figure 3.6A). In addition, qPCR analysis confirmed mRNA transcripts 
for glucose transporter’s, lactate dehydrogenase, insulin, and insulin receptor were not increased 
in CKO mice compared to WT controls (Figure 3.6B). Notably, no functional NCB5OR 
transcripts were detected in the cerebellum of both male and female CKO mice (Figure 3.6B). 
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Interestingly, male CKO mice also exhibited a lowered rate of respiratory water 
expulsion (vH2O) over WT controls during both the light (Figure 3.7A) and dark (Figure 3.7D) 
cycles.  This corresponded with a significant decrease in total water consumption (Figure 3.7E) 
and number of drinking bouts (Figure 3.7F) in CKO male mice during the dark cycle. It is 
important to note that female CKO mice maintained a normal vH2O (Figure 3.7D) when 
compared to controls but had an increased number of drinking bouts during the dark cycle 
(Figure 3.7F). These observations are consistent with a decreased hydration state in male, not 
female, CKO mice (Figure 3.1C). 
3.3.4 Male CKO mice exhibited changes in fasted feeding behavior.   
We observed no changes in normal feeding behavior between CKO and WT control mice 
(Figures 3.8A-D).  While there were no overt changes in ad libitum feeding in CKO mice, we 
observed differences in feeding behavior under fasted and refeeding conditions (Figure 3.9A-C). 
Upon resumption of ad libitum feeding after an overnight fast, male CKO mice gained 
approximately 11.5% of their fasted body weight in the 24 hours after feeding had resumed 
compared to the 5% gained by male WT mice. Conversely, female CKO gained 2.5% of their 
fasted body weight compared to the 5% gained by female WT mice. All CKO and WT mice 
were allowed ad libitum access to water at all times. 
3.3.5 Male CKO mice had normal serum T3, cortisol, and prolactin levels but elevated leptin 
levels.  
 Increased weight gain during refeeding after fasting, reduced voluntary exercise, and 
elevated RQ with no apparent explanation led us to investigate whether male CKO mice 
alterations in hypothalamic-pituitary-adrenal (HPA) axis function, hypothalamic-pituitary-
thyroid (HPT) axis function, or hypothalamic response to satiety cues.  .  Therefore, we 
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evaluated serum T3, cortisol, prolactin, and leptin levels.  When compared to WT controls, male 
CKO mice had normal serum T3 (Figure 3.10A), cortisol (Figure 3.10B), and prolactin levels 
(Figure 3.10C), but their leptin levels were significantly increased (Figure 3.10D).   
3.4 DISCUSSION AND CONCLUSIONS 
The cerebellum was once thought to influence only motor coordination, planning, and 
sensorimotor integration.  This view has since changed with a growing body of evidence 
indicating an integral role for the cerebellum in non-somatic and visceral functions including 
feeding, micturition, immune function, and emotional and higher order cognate processes (for 
reviews see  (Dietrichs, Haines, Roste, & Roste, 1994; Haines, Dietrichs, Mihailoff, & 
McDonald, 1997; Hoche et al., 2015; J. N. Zhu, Yung, Kwok-Chong Chow, Chan, & Wang, 
2006)). This study provides evidence that absence of a reductase, NCB5OR, in the cerebellum 
and midbrain of mice results in changes consistent with altered cerebellar-hypothalamic pathway 
function.  
Previous studies revealed an increased basal metabolic rate (vO2) and lower body weight 
in mice globally deficient for NCB5OR (Xu et al., 2011). In the current study, initial observation 
indicated that deleting NCB5OR in the cerebellum and midbrain resulted in normal body weight 
accompanied by a lowered vO2 and total energy expenditure in male CKO mice.  Generally, such 
results would indicate a lower basal metabolic rate with decreased appetite and food intake. 
Theoretically, this combination would balance the lowered caloric energy expenditure with a 
lowered caloric intake, resulting in normal body weight. However we did not observe changes in 
ad libitum feeding behavior in CKO mice compared to WT.  Further investigation revealed that 
male CKO mice had normal resting energy expenditure and participated significantly less in 
voluntary exercise during those times in which we observed lowered vO2 and energy 
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expenditure. Therefore we concluded that CKO mice do not have changes in basal metabolic rate 
or resting energy expenditure. Rather, male CKO mice have decreased locomotor activity during 
times in which peak activity is expected (dark cycle).  This observation is consistent with our 
previous study detailing altered locomotor behavior in CKO mice. However, the finding is novel 
in that these data indicate male CKO mice might have an aversion to voluntary wheel running in 
the absence of ataxia; an activity normally reveled by mice.  
Respiratory quotients (RQ) provide information about the status of metabolic substrate 
utilization in an animal by dividing the amount of CO2 eliminated by the amount of O2 consumed 
during respiration.  Normal RQ values generally range from 0.7, indicating pure fat oxidation, to 
1.0, indicating pure carbohydrate oxidation. These values are helpful in assessing metabolic 
substrate preference and have been helpful in identifying metabolic deficiencies and trends in 
disease (Korenaga et al., 2013; Nakaya et al., 1998). During rest (e.g. sleep or prolonged periods 
of immobility) or in a fasted state, RQ values are expected to be close to 0.70 due to a reliance on 
fatty acid utilization.  This preference is apparent in male WT mice during rest as indicated by 
resting RQ values of ~0.70. However, male mice lacking NCB5OR in the cerebellum and 
midbrain have elevated RQ values, even during rest, suggesting a state of mixed carbohydrate 
and fatty acid utilization. Since RQ values in male CKO mice indicated an increase in glucose 
utilization, it was within reason to consider the possibility that the neural tissue devoid of 
NCB5OR might have an increased basal metabolic rate comparative to the rest of the animal, 
causing increased glucose metabolism and the resulting elevated RQ values. However, transcript 
data for mRNA from CKO and WT mice failed to reveal increases in transcripts responsible for 
or attributed to changes in glucose uptake or demand in the brain. Transcript data would be 
unlikely to detect small changes in metabolic rate; however, considering the limited region in 
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which NCB5OR was deleted combined with the size of effect on RQ value, we posited that the 
change in metabolic activity would need to be sizeable, requiring significant changes in glucose 
uptake. In addition, a detectable increase in RQ value due to glucose preference derived from 
neural tissue would result in an increased basal metabolic rate (vO2) since glucose is the primary 
source of energy for neural tissue. However, we did not observe any changes in resting vO2 or 
energy expenditure in CKO mice. This data supports the observation that CKO mice do not have 
increased uptake of 
14
C-labeled 2-deoxyglucose in the cerebellum. 
Hydration and drinking behavior are controlled by extremely complex neuroendocrine 
mechanisms that have yet to be fully understood (for review see (Antunes-Rodrigues, de Castro, 
Elias, Valenca, & McCann, 2004)).  Angiotensin II (AT2) is a peptide hormone that plays a 
central role in the regulation of thirst and drinking behavior in the central nervous system 
((Franci, Kozlowski, & McCann, 1989), for reviews see (Daniels, 2016; Thornton, 2011)). The 
expression of AT2 receptors is generally restricted in the brain but has been confirmed in the 
cerebellum (Z. Huang et al., 2013; Lenkei, Palkovits, Corvol, & Llorens-Cortes, 1997). Direct 
projections from the deep cerebellar nuclei to osmoresponsive neurons in the paraventricular 
hypothalamus have been identified and neuroimaging evidence supports the theory that the 
cerebellum contributes to thirst (Parsons et al., 2000; Wen, Zhu, Zhang, & Wang, 2004). In our 
model, we observed significantly decreased levels of free and total water in CKO mice compared 
to WT controls. Changes indicative of altered thirst sensing were further observed in male CKO 
mice who had decreased water expulsion during exhalation (vH2O) accompanied by decreased 
water intake. We did not see this trend in female CKO mice, which could be explained by the 
effects of estrogen on drinking behavior and fluid intake in females (Santollo & Daniels, 2015a, 
2015b) as well as sexual dimorphism in AT2 mediated processes (Xue, Johnson, & Hay, 2013). 
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Our data indicate that male CKO mice have an altered thirst response leading to a state of 
dehydration or hyperosmolality.  Interestingly, hyperosmolality leads to a shift in metabolic 
substrate utilization similar to what is seen in male CKO mice: increased glucose utilization and 
decreased lipid oxidation leading to elevated RQ values (Keller, Szinnai, Bilz, & Berneis, 2003).   
The hypothalamus controls whole body thermoregulation and energy expenditure; 
however the exact mechanism by which this occurs is not fully understood.  In 2010 Lopez et al 
proposed and provided evidence for a mechanism by which T3 stimulates the ventromedial 
nucleus of the hypothalamus (VMH) which results in up regulated thermogenic markers in 
brown adipose tissue (Lopez et al., 2010). Investigators demonstrated phenotypes consistent with 
hyperthyroidism including weight loss due to increased energy expenditure and decreased fat 
mass after intracerebroventricular treatment with T3. While we observed no differences in body 
weight under ad libitum feeding conditions, we did observe a significant difference in male CKO 
body weight after an overnight fast.  Since serum T3 levels were unchanged, it is possible that 
the VMH in male CKO mice has an altered response to T3 stimulation under conditions of 
caloric restriction, possibly mediated by reciprocal cerebellar-hypothalamic circuitry. However, 
further experimentation is needed to understand the nature of these changes.  
A role for the cerebellum in the modulation of appetite and feeding behavior has been 
proposed based on mounting evidence that dysfunction or lesion in the cerebellum can result in 
changes in feeding behavior.  Evidence for a circadian oscillator involved in food anticipatory 
behavior has been found in mice with the hotfoot mutation (Grid2
ho/ho
), which results in altered 
cerebellar function and an ataxic phenotype (Mendoza et al., 2010).  Interestingly, food-restricted 
hotfoot mutant mice lacked food anticipatory behavior in the presence of normal corticosterone 
levels. HPA-regulated corticosterone levels play an integral role in food anticipatory behavior 
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and change according to food anticipatory trends (Diaz-Munoz, Vazquez-Martinez, Aguilar-
Roblero, & Escobar, 2000), suggesting that cerebellar modulation might involve the integration 
of peripherally expressed signals. However, we did not observe alterations in ad libitum feeding 
in the presence of normal corticosterone levels in CKO mice, indicating that corticosterone-
mediated regulation of ad libitum food intake is intact in CKO mice. 
Another peripherally expressed modulator of feeding behavior is leptin. Leptin is 
expressed by adipose tissue and plays a central role in mediating satiety during feeding 
(Friedman & Halaas, 1998). A vast majority of studies on leptin action in the brain have focused 
around the hypothalamus (van Swieten, Pandit, Adan, & van der Plasse, 2014), however leptin 
receptor expression in the brain appears to be widespread, suggesting that leptin may play more 
complex roles than previously thought (Bennett et al., 1998). Studies have confirmed the 
presence of leptin receptors in the cerebellum, with the active isoform found to be most densely 
expressed in the cerebellum (Burguera et al., 2000; Guan, Hess, Yu, Hey, & vanderPloeg, 1997).  
Leptin has also been shown to promote cell survival in cerebellar Purkinje neurons as well as 
modulate posterior cerebellar morphology in response to food cues in adults who are genetically-
deficient for leptin (Berman et al., 2013; Oldreive, Harvey, & Doherty, 2008).  In our study, 
male mice deficient for NCB5OR in the cerebellum and midbrain were found to gain 
significantly more weight as a result of ad libitum feeding after an overnight fast even in the 
presence of significantly elevated leptin levels.  Interestingly, female CKO mice had an opposite 
response to the fasted and refeeding conditions compared to their male counterparts with results 
demonstrating significant reductions in weight gained after resumption of feeding compared to 
WT controls.  The reason for the difference in this response is not immediately evident, although 
previous studies show sexually dimorphic responses to fasting as it pertains to corticosterone and 
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hypothalamic activation (Forbes, Herzog, & Cox, 2012; Fukushima et al., 2015). These changes 
are suggestive of an abnormal peripheral response to fasting conditions between the two 
genotypes and an abnormal response to satiety cues in the central nervous system (CNS).  
The regulation of leptin secretion from adipocytes has been linked to a number of 
different factors, including prolactin mediated inhibition of leptin secretion (42). Previous studies 
demonstrating interaction and reciprocal regulation of prolactin and leptin lead us to hypothesize 
that lowered prolactin levels might explain increased leptin levels in male CKO mice. However, 
there were no significant differences in serum prolactin levels between CKO and WT mice. 
Prolactin release is negatively regulated by hypothalamic dopaminergic stimulation of pituitary 
dopamine D2 receptors (D2R) and has been shown to be stimulated by chronic elevation of 
leptin levels (43-45).  Therefore, the lack of increased prolactin levels in the presence of 
increased basal leptin levels might indicate a decreased response to leptin. It is important to note 
that this response may not be an indication of changes in leptin sensitivity specifically, but rather 
increased hypothalamic dopaminergic tone leading to subsequent increased inhibition of 
prolactin release. We have previously observed changes in CKO mice indicative of altered 
dopaminergic function (see footnote 1) as well as significantly elevated dopamine levels in the 
brains of mice globally deficient for NCB5OR (unpublished data). Dopaminergic signaling in 
leptin-mediated processes has been explored and leptin modulation of dopaminergic tone in the 
ventral tegmental area (VTA) has been shown to reduce the reward response to running, leading 
to decreased voluntary exercise (46, 47). Direct dopaminergic projections from the VTA to the 
cerebellum have also been described (48). In addition, the actions of leptin-mediated satiety cues 
have been shown to be increased in the absence of hypothalamic D2R (49), and stimulation of 
adipocyte D2R has been shown to increase leptin secretion (50).  While CKO mice display 
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characteristic changes of altered hypothalamic function, the effects of leptin, prolactin, and 
dopamine on food intake in the CNS are considerably complex processes involving many 
factors.  Therefore, the effect of NCB5OR deficiency on hypothalamic function and leptin 
response in the CNS cannot be determined from the present findings and warrants future study. 
In summary, this study provided evidence that loss of NCB5OR in the cerebellum and 
midbrain likely affects pathways and processes mediated by cerebellar-hypothalamic circuitry, 
specifically, by altering the integration of peripheral signals regulating feeding and drinking 
behavior. Lack of NCB5OR in the cerebellum and midbrain altered neuroendocrine thirst 
regulation in a manner that resulted in dehydration and subsequently elevated RQ values due to a 
shift to glucose utilization. In addition, NCB5OR deficiency in the cerebellum and midbrain 
reduced energy expenditure due to lowered voluntary wheel running, which may be an indication 
of altered leptin-mediated reward response to exercise. Although further experimentation is 
needed to investigate the mechanism, our current data demonstrate a role for NCB5OR in 

































Figure 3.1 Hydration status of CKO and WT mice. (A)  Total water was significantly reduced in 
CKO mice compared to WT mice. (B) CKO mice had comparable free water content relative to 
WT controls. (C) Hydration ratios in male CKO mice were significantly lower than those of WT 
controls, while female CKO hydration ratios remained unchanged. See materials and methods for 
definitions and calculations. Values are presented as means ± SEM (standard error of mean). *, p 




Figure 3.2 Exercise trends in CKO and WT mice. (A, B) Longitudinal representations of 
cumulative meters during two consecutive light and dark cycles. Note the lack of distance 
accumulation during the light cycle in (A). There were no differences between CKO and WT 
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mice during the light cycle for (C) average wheel distance traveled per cycle and (D) average 
pedestrian locomotion distance per cycle. Significantly lowered average wheel distance traveled 
in male CKO mice compared to WT during the dark cycle is shown in (E), while there were no 
differences in pedestrian locomotion (F).  See materials and methods for definitions. Values are 
presented as means ± SEM (standard error of mean). Light and shaded areas in (A) and (D) 
represent light and dark cycles, respectively. *, p<0.05. n=12 for CKO (6 Male, 6 Female) and 




















Figure 3.3 Gait analysis and Rota-rod performance in CKO mice. (A) CKO mice did not display 
changes in gait symmetry or (B) Rota-rod performance, indicating no overt signs of ataxia. 
Values are presented as means ± SEM (standard error of mean). n=9 for CKO (4 Male, 5 





Figure 3.4 Energy expenditure and oxygen consumption in CKO and WT mice. Average rate of 
oxygen consumption (vO2) was comparable between WT and CKO mice during the light cycle 
(A), but was lower in male CKO mice during the dark cycle (B). (C) Total energy expenditure 
(EE) was unchanged in CKO mice during the light cycle, but (D) was lower in male CKO mice 
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during the dark cycle. (E, F) Resting EE was unchanged between WT and CKO mice during both 
light and dark cycles. See materials and methods for definitions. Values are presented as means ± 
SEM (standard error of mean) and were normalized to body weight (per g bw). *, p<0.05. n=12 






































































































































































































































































































































































































































































































Figure 3.6 Status of glucose uptake in the CKO cerebellum. (A) CKO mice do not show altered 
uptake of 
14
C labeled 2-DoG in the cerebellum relative to WT controls. (B) Transcript levels of 
genes involved in glucose transport and lactate metabolism in the cerebellum of 16 week old 
CKO and WT mice. Transcript levels were determined by defining the internal reference, 18S 
rRNA, as 10
6
.  Ins2, insulin; InsR, insulin receptor; LdhA, lactate dehydrogenase A; Glut1, 
glucose transporter 1, Glut3, glucose transporter 3. For 2-DoG uptake, n=10 WT (5 Male, 5 
Female) and n=10 CKO (5 Male, 5 Female). For qPCR n=8 WT (4 Male, 4 Female) and n=8 KO 
(5 Male, 3 Female). Values are presented as means ± SEM (standard error of mean). CPM is 










Figure 3.7 Respiratory water expulsion and water consumption behavior. During the light cycle, 
male CKO mice had (A) lowered average respiratory water consumption (vH
2
O) but consumed 
comparable amounts of water (B) and had comparable average number of bouts (C) compared to 
WT mice. During the dark cycle, male CKO mice had (D) lowered average vH
2
O along with 
decreased average water consumption (E) and average number of drinking bouts (F). Note that in 
(F), female CKO mice had an elevated number of drinking bouts converse that of their male 
counterparts. See materials and methods for definitions. Values are presented as means ± SEM 
(standard error of mean) and were normalized to body weight (per g bw) in (A, D). *, p<0.05; 









Figure 3.8 Feeding behavior of individually housed CKO and WT mice. CKO mice consumed 
the same amount of food compared to WT mice during both the light cycle (A) and dark cycle 
(B).  There were no differences in the number of feeding bouts between WT and CKO mice 
during either the light cycle (C) or the dark cycle (D). Values are presented as means ± SEM 









Figure 3.9 Fasted feeding weight change in CKO mice. (A) Male CKO mice displayed 
decreased body weight after an overnight fast and (B) after resuming ad libitum feeding for 24 
hours. (C) Male CKO mice gained significantly more body weight after refeeding while female 
CKO gained less compared to WT controls.  All mice have access to water ad libitum at all 
times. Values are presented as means ± SEM. * p<0.05; ***, p<0.005. n=12 for CKO (6 Male, 6 













Figure 3.10  Serum T3, cortisol, prolactin, and leptin levels in male CKO mice. There were no 
differences in serum T3 (A), cortisol (B), or prolactin (C) levels between male CKO and WT 
mice. However, male CKO mice had significantly elevated serum levels of leptin (D) relative to 
WT controls. Values are presented as means ± SEM (standard error of mean). ***, p<0.005. 













EVALUATION OF NEUROTRANSMITTER LEVELS IN THE NCB5OR-DEFICIENT 













Iron is an essential nutrient required for proper brain development and function. Early studies 
established that early life brain iron deficiency, genetic or otherwise, affects neurotransmitter 
levels, ultimately altering proper development and functioning of neural pathways.  Ablation of 
NCB5OR in the mouse cerebellum has been shown to affect iron homeostasis, feeding behavior, 
and locomotor activity.  This study aimed to assess whether loss of NCB5OR in the mouse brain 
resulted in changes in four primary neurotransmitters in the cerebellum and frontal cortex: 
serotonin (5-HT), dopamine (DA), gamma aminobutyric acid (GABA), and L-glutamic acid 
(Glut). Using hydrophilic interaction liquid chromatography (HILIC) ultra-performance liquid 
chromatography coupled electrospray tandem mass spectrometry (UPLC-MS/MS) we 
determined that 10 week old, non-diabetic female mice globally deficient for NCB5OR (GKO 
mice) had normal levels of 5-HT, GABA, and Glut in the cerebellum and cortex compared to 
wildtype controls. However, cortex DA levels were found to be significantly elevated in GKO 












4.2 INTRODUCTION  
 Neurotransmitter levels are suspect in a number of neurological and psychological 
diseases. As such, metabolic pathways and receptors responsible for neurotransmitter synthesis, 
breakdown, and signal transduction are often key targets in etiological and pharmacological 
studies.  There is a growing body of evidence that neurological diseases and disorders may be 
strongly influenced by a number of environmental factors, including nutrition.  Iron deficiency 
has long been recognized as the number one nutritional deficiency in the world (WHO, 2001). 
Early studies investigated the impact of dietary iron deficiency on neurotransmitter levels and 
behavior as well as the functions of enzymes and pathways responsible for the synthesis, 
breakdown, and action of many neurotransmitters (J. L. Beard, Chen, Connor, & Jones, 1994; 
Oski, Honig, Helu, & Howanitz, 1983; Youdim & Green, 1978).  The revelation that iron status 
alters neurotransmitter networks has since resulted studies investigating neurotransmitter 
composition and brain function in diseases, genetic models, and conditions in which iron 
homeostasis is known to be perturbed (Bakoyiannis et al., 2015; J. Beard, 2003; Johnstone & 
Milward, 2010; J. Kim & Wessling-Resnick, 2014).  
We recently reported that global ablation of a reductase, NCB5OR, results in iron 
dyshomeostasis and hyperactivity in mice (see Chapter 1, footnotes 2 and 3). In addition, we 
observed alterations in iron pathways, iron uptake, and locomotor response to dietary iron 
deficiency in mice deficient for NCB5OR only in the cerebellum and midbrain (see Chapter 2).  
These changes led us to hypothesize that loss of NCB5OR would alter neurotransmitter levels in 
the brain. Therefore we investigated whether global loss of NCB5OR would lead to changes in 
serotonin (5-HT), dopamine (DA), γ-Aminobutyric acid (GABA), and L-glutamic acid (Glut) 
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levels in the mouse cerebellum and cortex using hydrophilic interaction ultra-performance liquid 
chromatography tandem mass spectrometry (HILIC UPLC-MS/MS).  
The separation and quantification of pure monoamine neurotransmitters using HILIC 
UPLC-MS/MS has been previously described methodologically (Danaceua, 2012). However, the 
use of HILIC to assess neurotransmitter levels in biological samples, namely brain tissue, has yet 
to be described. In addition, non-monoamine neurotransmitters such as GABA and Glut were not 
included in the previous method description.  Therefore we modified and optimized the 
previously described method for simultaneous separation of 5-HT, DA, GABA, Glut and 3,4-
dihydroxybenzylamine (DHBA).  DHBA is a dopamine analog and is used as an internal 
standard (IS) in our study. In addition, we developed a method to effectively extract quantifiable 
amounts of all 4 neurotransmitters from mouse brain tissue. 
4.3 METHOD VALIDATION AND RESULTS 
4.3.1 Assay Optimization.  
Chromatographic conditions were adjusted such that 5-HT, DA, GABA, Glut, and 
DHBA were independently identifiable peaks at consistent retention times (Figure 4.1). All five 
compounds were best detected in positive ion detection mode.  The conditions for detection of 
the most abundant protonated ion peak ([M + H]
 +
 for each compound are described in Table 4.1.  
Using these conditions we were able to establish ranges in which the peak response was linearly 
correlated with known amounts of compound (Table 4.2) and we were able to identify the lower 
limits of quantitation (LOQ) for each compound.  We did not determine the lower limit of 
detection (LOD) as the LOQ for all compounds was established using the lowest standard 




User and auto injector accuracy were tested in order to determine an expected error of 
measurement from the processes and to confirm that there were no systematic errors in the 
method (Table 4.1).  User accuracy was determined by quantifying mass spectra of injections 
from five independently prepared vials of a standard of known concentration.  Auto injection 
accuracy was determined by quantifying mass spectra of five successive injections from one vial 
of a standard of known concentration.  Accuracy was calculated as percent error.  User sample 
preparation accuracy and auto injection accuracy were comparable and were below 5%.  
4.3.2 Sample peak identification and assessment of matrix effects.  
A recurrent problem when assaying brain tissue for endogenous compounds using liquid 
chromatography is the lack of available analyte matrix, which is used to assess whether the 
presence of other compounds in the solution have an effect on the analyte of interest.  Therefore, 
test samples of cerebellar extract were used to identify compound peaks in the presence of matrix 
and to assess if matrix effects were present by utilizing a method of standard addition. 
Chromatography and mass spectra were collected for neurotransmitters and the internal standard 
(IS) DHBA from 5 μL and 2.5 μL injections of extract and diluted extract, respectively.  The 
same samples were then spiked to a 50 μM concentration (within the determined linear range for 
all compounds) with standard stock solutions of 5-HT, DA, GABA, DHBA, and Glut. Mass 
spectra were collected for neurotransmitters and the IS from 5 μL and 2.5 μL injections of spiked 
extract or spiked diluted extract, respectively. Mass spectra of normal and spike extract were 
compared and peaks were identified according to elevated peak responses at expected retention 
times for individual compounds. There were no significant shifts in retention times (< 0.10 min) 




4.3.3 Analysis of neurotransmitters in the GKO mouse cerebellum and cortex 
 Using the validated assay conditions for all compounds we established the best conditions 
for evaluating 5-HT, DA, GABA, and Glut levels in mouse brain tissue extract.  We determined 
that the extraction method was sufficient to yield quantifiable levels of all neurotransmitters as 
well as the added IS.  Since the levels of GABA and Glut are three and four orders of magnitude 
more abundant in mouse brain tissue, respectively, than 5-HT and DA, we determined that a 100 
fold dilution was sufficient to produce peak responses in the linear ranges for GABA and Glut.   
 We used the above assay conditions to quantify the levels of 5-HT, DA, Glut, and GABA 
in the cerebellum and frontal cortex of GKO and WT mice for comparison. Quantification of 5-
HT, DA, GABA, and Glut in the cerebellum revealed no significant differences in GKO mice 
relative to WT controls (Figure 4.3).  However, we observed significantly elevated levels of DA 
in frontal cortex extracts from GKO mice while 5-HT, GABA, and Glut remained unchanged 
relative to controls (Figure 4.3B).  
4.4 DISCUSSION 
Data presented here detail the analysis of four endogenous neurotransmitters in mouse 
brain tissue derived from mice globally deficient for NCB5OR.  We presented data pertaining to 
assay development and validation as well as the application of the assay to biological samples.  
Our data indicate that DA levels are modulated by loss of NCB5OR in the mouse frontal cortex 
but not in the cerebellum.   
 Manipulating brain iron levels has been shown to alter development, behavior, and 
neurotransmitter levels, and has been shown to have specific effects on dopamine and behaviors 
associated with dopaminergic function (for review see, (Lozoff, 2011)).  Pioneering work by Dr. 
John Beard demonstrated regional alterations in brain dopamine levels as well as changes in 
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dopamine receptor densities as a result of iron deficiency (for review see, (J. Beard, 2003)). 
Studies have repeatedly demonstrated the specific effects of iron deficiency on dopamine levels, 
with dopamine levels elevating in the context of iron deficiency while other neurotransmitters 
remain unchanged (J. L. Beard et al., 1994; Erikson, Jones, Hess, Zhang, & Beard, 2001; Nelson, 
Erikson, Pinero, & Beard, 1997).  In addition, studies support findings that suggest early life iron 
deprivation leads to permanent alterations in behavioral profiles and dopaminergic networks (for 
review see (Georgieff, 2011)).   
Loss of NCB5OR in the mouse cerebellum and midbrain has been shown to lead to 
alterations in brain iron homeostasis as well as locomotor changes indicative of altered 
dopaminergic function (see Chapter 2). Mice globally deficient for NCB5OR display hyperactive 
behavior (see preliminary data, Chapter 1), a phenotype known to result from changes in both 
iron homeostasis and dopaminergic function in the mesocorticolimbic system (Ohno, 2003; 
Viggiano & Sadile, 2000). Hyperactivity in GKO mice is consistent with our observations of 
increased dopamine levels in the cortex of GKO mice. Iron deficiency has been shown to alter 
the activities of dopamine hydroxylase, monoamine oxidase, dopamine transporters, and 
dopamine receptors. This data, combined with observations presented in Chapters 2 and 3, 
suggest a significant impact of NCB5OR deficiency on dopaminergic networks. Still, 
significantly more work is needed to identify the exact mechanism by which NCB5OR 



































Figure 4.1 Chromatography of 5-HT, DA, DHBA, GABA, and Glut using HILIC UPLC 
MS/MS.  Chromatographic conditions were optimized to allow for 7.5 minute run times and 
distinct and acceptable peak resolution and shape. Note that the most polar (hydrophilic) 
compounds had the shortest retention times. DHBA is an analog of DA that varies by only one 
methylene group, leading to their close, but distinct, retention times. All peak retention times 

















Table 4.1 LC-MS/MS analytical parameters. All compounds were best detected in positive ion 
mode. The most abundant [M + H]
+ 
peak was selected and used for quantification.  5-HT; 
serotonin. DA; dopamine. GABA; γ-aminobutyric acid. Glut; l-glutamic acid. DHBA; 3.4-
dihydroxybenzylamine. RE; relative error. RE is an average of RE’s obtained from 5 replicate 


































5-HT 177.5 20 11 160.8 4.75 User 
(sample prep) 
Injection 
DA 154.1 11 21 136.9 4.98 
GABA 103.9 16 15 86.6 5.74   
Glut 148.1 22 9 83.8 6.67 3.2 4.8 





Table 4.2 Compound calibration parameters for quantification using HILIC UPLC-MS/MS. Due 
to the wide detection range for each compound as well as relative abundance in normal and 
diluted biological samples, separate calibration curves were established for DA and DHBA. All 
calibration curves were established from the same standard curve run, but were adjusted based 
on detected range so as to provide more accurate quantitation. LOD; limit of detection. LOQ; 
























5-HT y=0.0006x-0.4066 0.03-133 0.9950 < 0.02 0.02 
DA (cer.) y=0.0001x-0.0151 0.02-0.74 0.9966 < 0.02 0.02 
DA (cort.) y=0.00009x-0.0046 0.02-23.7 0.9973 < 0.02 - 
GABA y=0.0002x-0.1477 0.01-64.5 0.9997 < 0.02 0.03 
Glut y=0.0708x-1.1379 2.64-106 0.9999 < 0.02 0.02 
DHBA (5-HT, 
DA) 
y=0.0012x-0.0206 0.03-27.5 0.9997 < 0.02 0.02 
DHBA (GABA, 
Glut) 





Figure 4.2 Identification of compound peaks and matrix effects in cerebellar extract.  Pure 
cerebellar extract spiked with DHBA as an internal standard (IS) was evaluated for peak 
identification (LEFT).  5-HT and DA display multiple auxiliary peaks from unidentified 
endogenous compounds. Without a matrix blank to assess matrix effects, it is not possible to 
conclude that the peaks observed at the expected retention times are actually 5-HT and DA. 
(RIGHT) Addition of a pure compound standard to the cerebellum extract leads to enhanced 
peak response near the expected retention times of each compound, confirming the presence and 
placement of detectable endogenous 5-HT and DA.  No significant shift in retention time or 
change in expected spike recovery values were observed, indicating no apparent matrix effects. 
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Figure 4.3 5-HT, DA, GABA, and Glut levels in the cerebellum and cortex of GKO and WT 
mice. (A) Levels of 5-HT were did not differ in the cerebellum or cortex of GKO mice relative to 
controls. (B) Cortex DA levels are significantly increased in GKO mice relative to controls while 
no change was observed in the cerebellum. (C&D) GABA and Glut levels were comparable 
between GKO and WT mice in the cerebellum and cortex. n= 3:3 (KO:WT). Values are 




















































5.1 CHAPTER 2 MATERIALS AND METHODS 
5.1.1 Conditional knock out and reporter mice.  
All mice were of C57BL/6J background and treated according to the University of 
Kansas Medical Center’s Institutional Animal Care and Use Committee approval protocol. The 
generation of mice with selective deletion of NCB5OR in the mouse cerebellum and midbrain 
(conditional knockout (CKO) mice) was achieved by crossing C57BL/6J mice homozygous for a 
floxed version of NCB5OR’s exon 3 (detailed in Wang et al, see footnote 2) with En1
tm2(cre)Wrst
 
(The Jackson Laboratory stock no. 007916) mice that are known to excise floxed DNA regions 
in only the cerebellum and midbrain (Kimmel et al., 2000).  To evaluate recombination activity, 
En1 Cre positive mice were crossed with B6.Cg-Gt(ROSA)26Sor
tm14(CAG-tdTomato)Hze/J
 (stock no. 
007914, Jackson Laboratory) which harbor a TdTomato locus with a loxP-flanked STOP cassette 
that was removed after Cre-mediated recombination, resulting in TdTomato expression. Mice 
carrying no copies of the Cre gene were considered as normal or wild-type (WT) and all mice 
used (CKO and WT) were littermates. Evaluation of recombination of NCB5OR was also 
conducted using qPCR and primer sets targeted to exon 3 and exon 4 of NCB5OR transcripts. 
5.1.2 TdTomato reporter and confocal microscopy. 
Tandem dimer Tomato (TdTomato) reporter mice underwent transcardial perfusion with 
10 mL of PBS solution immediately followed by 10 mL of 4% paraformaldehyde. The 
cerebellum was collected and immediately post-fixed with 4% paraformaldehyde at room 
temperature for 1 hour.  Tissue was then transferred to 20% sucrose solution and allowed to sit 
overnight at 4°C for cryoprotection. Tissues were then embedded in OCT and 12 µm sections 
were cut, placed on Superfrost Plus slide (Fisher, #12-550-15), and cover slipped.  Confocal 
images of TdTomato were taken using a Nikon Eclipse 90i microscope. 
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5.1.3 Molecular analysis.   
Quantitative Reverse Transcription PCR (qRT-PCR) was performed on RNA extracted 
from WT and CKO whole mouse cerebellum after the mice had been fasted for 4 hours. Purity of 
isolated RNA was assessed by A260/A280 ratio. Reverse transcription of 1ug total RNA was 
performed using M-MLV Reverse transcriptase and standard protocol from Life Technologies 
(Cat # 28025-013). The qPCR reaction was performed on an Applied Biosystems 7900 Fast 
Real-Time PCR System using SYBR Green master mix from ThermoFisher (Cat. No. 4367659) 
and all results were normalized to 18S rRNA with the ∆∆Ct method. Primer sequences are 
available upon request. Total protein was isolated from whole mouse cerebellum using a lysis 
buffer as previously described (Lemaire-Vieille et al., 2013), with the addition of the 
SigmaFAST protease inhibitor cocktail (s8830).  Protein content was determined using a DC 
assay from Bio-Rad, and total protein was diluted with SDS loading buffer containing β-
mercaptoethanol and boiled briefly at ~95°C for 5 minutes.  Ninety (90) µg of total protein per 
sample underwent gel electrophoresis on a mini protean TGX gel 4-15% from BioRad (Cat. No. 
456-1084). Protein was transferred to a nitrocellulose membrane via cold transfer at 200 mA for 
2 hours while at 4°C.  Transfer buffer was composed of 25 mM Tris-base (pH 8.8), 192 mM 
glycine, and 20% methanol. All antibodies are against mouse antigen: Actin (Sigma, # A1978), 
APP (Cell Signaling, 2452), ferritin heavy chain/FtH (Santa Cruz Biotechnology, sc-14416), and 
transferrin receptor 1/TfR1 (Invitrogen, 13-6800). Densitometry was performed using ImageJ 
software. Percentages represent percentage of signal that is attributed to protein band over the 
background noise (% Protein or % FtH). Densitometry signal of each protein is normalized 






Fe uptake.  
Iron uptake in the cerebellum, spleen, and liver was determined by oral 
59
Fe ingestion. 
Mice were fasted overnight (14-16 hours) but allowed water ad libitum. Each mouse underwent 
intragastric feeding with a solution containing 10 µCi/mL of 
59
Fe, 30 µg/mL carrier iron, and 1 
M ascorbic acid in phosphate-buffered saline as previously described (Du et al., 2008). Each 
mouse received 2 µCi
 59
Fe per 10 grams of body weight.  One (1) hour post oral gavage, feeding 
of chow was resumed ad libitum. Approximately 24 hours post-gavage the brain, cerebellum, 
spleen, and liver were collected. Radioactivity was measured (each in a total volume < 1 mL) 
using a Perkin Elmer 1470 Wizard gamma counter.  
5.1.5 Non-heme iron content.  
Tissue non-heme iron content was measured as previously described (Torrance & 
Bothwell, 1968). Whole cerebellum and spleen from mice were dried at 55°C for > 48 hours, 
ground into powder, weighed, and then digested in 200 µL or 1 mL of 10% trichloroacetic 
acid/10% HCl at 55°C for > 48 hours, respectively. Samples were then centrifuged at 16,000 rcf 
for 10 minutes and 100 µL of the supernatant collected. Ten (10) µL of supernatant was then 
mixed well in a clear-bottom 96-well plate with 190 µL of chromogen solution, allowed to 
incubate for 10 minutes at room temperature, and the absorbance at 535nm was determined using 
a Tecan Plate Reader. Chromogen solution consisted of 0.01% bathophenanthroline-disulfonic 
acid, 0.1% thioglycolic acid, and 7 M sodium acetate. Iron concentration was determined by a 
standard curve dilution from an iron standard (Sigma, St. Louis, MO).  All measurements were 





5.1.6 Histology and iron staining.   
Sixteen (16) week old male CKO and WT mice were fasted for 4 hours and then 
sacrificed. Whole blood and cerebellum were collected. The cerebellum was immediately placed 
in 4% paraformaldehyde and allowed to sit at room temperature for 1-2 hours and then placed at 
4°C overnight.  The paraformaldehyde was then replaced with 70% ethanol and the cerebellum 
was stored at 4°C until processing.  The cerebellum underwent dehydration processing and was 
embedded in paraffin wax for sectioning. Ten (10) µM sections were taken and placed on 
Superfrost Plus slide (Fisher, #12-550-15).   
 Perls’ Prussian blue iron staining with DAB enhancement was performed on sections, as 
previously described (Moos & Mollgard, 1993; Nguyenlegros, Bizot, Bolesse, & Pulicani, 1980; 
Roschzttardtz, Conejero, Curie, & Mari, 2010; M. A. Smith, P. L. R. Harris, L. M. Sayre, & G. 
Perry, 1997).  Prior to staining, sections were rehydrated and during the rehydration sequence a 
3% H2O2 step was added before the final rehydration step for quenching of endogenous 
peroxidases.  Sections were then stained with 3% HCl / 3% potassium ferrocyanide / 2% Triton 
100X solution for 30 minutes and subsequently washed with distilled H2O for 10 minutes.  DAB 
enhancement was performed for 15 minutes according to the manufacturer’s protocol (Thermo 
Fisher cat. No. 34065B). Sections were counterstained with Nissl (cresyl violet). Iron positive 
and total Purkinje cell counting was performed with a manual counter in real time on a total of 
22 sections (10 CKO, 12 WT; 8047 total cells counted). Observer was blinded to genotype 
during counting.   
5.1.7 Dietary treatment.  
Mice were switched to a low-iron diet (TD10210, Teklad Harlan) and allowed to feed ad 
libitum beginning at weaning (3 weeks of age) and continued for 4 weeks until 7 weeks of age.  
127 
 
5.1.8 Longitudinal behavior assays and gait analysis.  
Beginning at 3 weeks of age mice fed either a chow or low-iron diet were screened using 
a battery of behavioral tests on a weekly basis until 7 weeks of age. The battery of behavioral 
tests included stationary elevated beam walk, Force-plate Actimetry (BASi), and fore/whole 
body grip strength. Mice were tested beginning early in the morning (around the beginning of the 
programmed light cycle of 7 a.m.) and testing was finished prior to noon (12 p.m.) so as to avoid 
cortisol-associated effects on outcomes. At 7 weeks of age, mice were tested on the Rota-rod and 
underwent gait analysis using a DigiGait apparatus (Mouse Specifics) prior to euthanasia. Force-
plate Actimeter measurements were obtained during 10 minute recording sessions and DigiGait 
analysis was conducted at a walking speed of 10 cm/s. Rota-rod data were collected at an 
accelerating speed of 4 to 40 rpm for a maximum of 5 minutes. 
5.1.9 Sucrose preference test.   
At 6 weeks of age, mice fed a low-iron or chow diet were individually housed in a two 
bottle system cage with both bottles containing water. After 1 day of acclimation, one bottle was 
replaced with a pre-weighed bottle of 4% sucrose solution and the amount of water in the non-
sucrose bottle was measured.  The positions of water and sucrose solutions were randomized 
between cages. After 24 hours both the water and sucrose solution weights were recorded and the 
net consumptions for water, sucrose, and total liquid were determined. 
5.1.10 Harmaline-induced tremor.  
At 24 weeks of age, mice were subject to a harmaline-induced tremor assay using 
subcutaneous injection of harmaline saline solution and assessment of tremor activity on a Force-
plate actimeter as previously described (F. C. Martin et al., 2005).  An initial baseline reading of 
activity for frequencies from 0-25 Hz was obtained by allowing mice to explore the Actimeter 
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for 10 minutes pre-injection. The mice were removed and 4 mL/kg of harmaline stock solution (5 
mg/mL harmaline in saline) was injected and the mice were immediately returned to the 
Actimeter for a 40 minute recording session.  During this time recordings for signals from 0-25 
Hz were collected.  Subsequently, Fourier transformation of the force-time data facilitated power 
analysis across frequency and the data was binned into 4 different epochs of 10 minutes per 
epoch. The MPP normalizes the data to give the specific contribution of tremor activity (activity 
in the 10-17 Hz range) to total motion activity over the 0-25 Hz range, allowing for corrections 
for intra-animal total movement variation. 
5.1.11 Statistical analyses.   
One (1) way ANOVA was performed for genotype comparison of Western blot 
quantification and for iron staining quantification of Purkinje cells. Two (2) way ANOVA (sex 
and genotype) analysis was performed for qPCR, 
59
Fe uptake, non-heme iron content, and all 
behavior tests. Three (3) way ANOVA (genotype, sex, and diet) was used to evaluate changes in 
body weight during the longitudinal studies, sucrose preference test data, and on all metrics from 
gait analyses. Three (3) way ANOVA (genotype, sex, and age) was used for gait analyses 
between 7 and 16 week old mice.  Student-Newman-Keuls post hoc tests were performed for all 
ANOVA’s. P-values of <0.05 were considered statistically significant.  Values are presented as 
mean +/- SEM (standard error of mean). 
5.2 CHAPTER 3 MATERIALS AND METHODS 
5.2.1 Generation of conditional knockout mice (CKO) and animal husbandry.  
All mice were treated according to the University of Kansas Medical Center’s 
Institutional Animal Care and Use Committee approval protocol.  All mice were of C57BL/6J 
background. The generation of CKO mice mice) was achieved as previously described (see 
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section 5.1.1).  Deletion of NCB5OR in the cerebellum was confirmed through qPCR analysis of 
functional NCB5OR transcripts, of which the loss of sequences corresponding to exon 3 results 
in a premature “stop” codon and a highly truncated protein product of 89 residues. All 
measurements were performed on mice at 16 weeks of age. Mice were fed a standard chow diet 
from PicoLab (5053). Chow diet total calorie composition: 62.4% carbohydrates, 24.5% 
proteins, and 13.1% fat. 
5.2.2 Transcript Analysis.   
Quantitative Reverse Transcription PCR (qRT-PCR) was performed on RNA extracted 
from WT and CKO whole mouse cerebellum after mice had been fasted for 4 hours. Total RNA 
purity was assessed by A260/A280 ratio. One (1) μg of total RNA underwent reverse transcription 
using the M-MLV Reverse transcriptase and random primers from Life Technologies (Cat # 
28025-013 and 48190-011, respectively). The qPCR reaction was performed on an ABI 7900 HT 
thermo system using SYBR Green master mix from ThermoFisher (Cat # 4367659) and all 
results were normalized to 18S rRNA with the ∆∆Ct method. Primer sequences are available 
upon request. 
5.2.3 Serum T3, Cortisol, Prolactin, and Leptin levels.   
Blood serum levels of T3, cortisol, prolactin, and leptin were evaluated using enzyme 
linked immunosorbent assay (ELISA) kits (T3, Sigma–SE120091; Cortisol, Sigma-SE120082; 
Prolactin, Sigma-RAB0408; Leptin, Abcam-ab100718). Sixteen (16) week old male CKO mice 
and WT littermate controls were fasted for 4-6 hours and whole blood was collected in BD 
Serum Separator Tube (Fisher Cat # 02-675-188) and centrifuged at 9,000 rcf for 10 minutes at 
4°C. Blood serum was then collected and immediately frozen using liquid N2 and stored at -80°C 
for use at a later date.  ELISA’s were performed according to manufacturer’s protocol. 
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5.2.4 Metabolic, feeding, drinking, and locomotion detection.  
Sixteen (16) week old CKO mice (n=12; 6 male, 6 female) and WT littermates (n=12; 6 
male, 6 female) were individually housed and analyzed using the Promethion Indirect 
Calorimetry System (Sable Systems, Inc., North Las Vegas, NV).  All mice were provided 
access to running wheels. Measurements of feeding, drinking, metabolism, sleeping, and 
locomotor activity were recorded for 3 days (3 light-dark cycles).  Data collected from the first 
day (1
st
 light-dark cycle) were discarded to avoid unintended effects and noise during 
acclimation. Light-dark cycles were in 12 hour intervals with the light cycle commencing from 
0700 to 1900 and the dark cycle commencing from 1900 to 0700.  
5.2.5 Gait analysis and Rota-rod performance.  
Conditional knockout and WT mice underwent gait analysis using a DigiGait apparatus 
(Mouse Specifics) and were tested on the Rota-rod as described in more detail elsewhere (see 
section 5.1.8). Briefly, DigiGait analysis was conducted under walking conditions at a speed of 
10 cm/s, and Rota-rod measurements were collected at an accelerating speed of 4 to 40 rpm for 
no longer than 5 minutes.  
5.2.6 Fasted-feeding assay.  
Mice were deprived of food overnight (~ 14 hours) before being allowed ad libitum 
access to food for 24 hours.  Mice were allowed ad libitum access to water at all times. 
5.2.7 Echo MRI.  
Animal body composition was assessed using the EchoMRI-1100 system (EchoMRI 





5.2.8 2-deoxyglucose (2-DoG) uptake.  
Mice were fasted for 4-6 hours prior to intraperitoneal injection of 0.15 uCi per gram 
body weight of 14C 2-deoxyglucose (Perkin Elmer, Cat # NEC-945A).  Whole cerebellum was 
collected 2 hours later and was placed in 1 mL of lysis buffer containing proteinase K, 
homogenized, and rotated at 55°C overnight. Whole homogenate was then mixed with a 
scintillation fluid (ScintiVerse BD cocktail, Fisher Cat # SX18-4) and 5 minute β-scintillation 
counts were obtained on a Beckman Coulter LS6500 Multi-purpose scintillation counter. The 
composition of the lysis buffer was as follows (final concentration): 100 mM Tris-HCl pH 8.8, 5 
mM EDTA, 0.2% SDS, 200 mM NaCl, 10 μg/mL proteinase K. 
5.2.9 Statistical analyses.   
Two (2)-way ANOVA (sex and genotype) with Student-Newman-Keuls post hoc test 
analysis was performed for qPCR and ECHO MRI. Two (2)-way ANOVA (sex and genotype) 
analysis with Student-Newman-Keuls post hoc test analysis was performed for all metabolic, 
locomotor, and feeding metrics after values had been split into light and dark cycles and 
averaged for two consecutive light and dark cycles. One (1)-way ANOVA (genotype) analysis 
was performed for all ELISA results. Simple linear regression analysis was performed in R for 
correlation between wheel activity and total energy expenditure and correlation between wheel 
activity and vO2. Pearson correlation analysis was performed in R for correlations between wheel 
activity and total energy expenditure and correlations between wheel activity and vO2 and a t-test 
was applied to individual correlations.  Pearson correlation values are presented as Pearson 
correlation coefficients. All other values are presented as means ± SEM (standard error of mean). 
P-values of <0.05 were considered statistically significant.  Alternative statistical analysis: In 
order to confirm observations made using the above statistical analysis, metabolic cage data were 
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analyzed using a three part analysis in R.  First, interactions between all three independent 
variables (genotype, sex, and cycle) were analyzed using a linear mixed effects (LME) model. 
This allowed for interactions between all three independent variables to be analyzed while 
avoiding an artificially inflated ‘n’ due to measures of light and dark cycles being from the same 
mice (e.g. 22 measurements for mice during the light cycle and 22 measurements for the mice 
during the dark cycle should be analyzed using an ‘n’ of 22 instead of ‘n’ of 44).   Next, 
ANOVA analysis was performed using results from the LME analysis. Finally, those interactions 
that yielded significant p-values (p<0.05) were further analyzed using a correlation matrix 
approach to delineate which interactions within the groups were significant. For example, if a 
significant interaction was found between genotype and sex, further analysis was used to 
determine if the significant difference between genotypes was found in the male or female 
populations. This analysis confirmed results and conclusions drawn from the original statistical 
analysis of metabolic cage data. 
5.3 CHAPTER 4 MATERIALS AND METHODS 
5.3.1 Chemicals and reagents.    
Pure analyte, internal standard, and antioxidant were purchased from Sigma: Serotonin 
(5-HT, 14927), Dopamine hydrochloride (DA, PHR1090), L-glutamic acid monosodium salt 
hydrate (Glut, 01495), γ-Aminobutyric acid (GABA, A2129) 3,4-Dihydroxybenzylamine 
hydrobromide (DHBA, 858781), L-Ascorbic acid (AA, A92902).  Reagents and HPLC grade 
liquids used for mobile phase preparation were purchased from Fisher: Ammonium Formate 





5.3.2 Preparation of Reagents and Standard Solutions.  
Mobile phase A (MPA) consisted of 95% ammonium formate (100 mM) set at pH 3.0 
with formic acid and 5% acetonitrile. Mobile phase B (MPB) consisted of 85% acetonitrile and 
15% ammonium formate (30 mM) set at pH 3.0 using formic acid. A 10 mM standard stock 
solution mix of DA, 5HT, GABA, and DHBA was made in HPLC grade methanol solution 
containing 1N HCl (2.5%) and ascorbic acid (1 mg/mL) to prevent oxidation. A 10 mM standard 
stock solution of Glut was made in a solution of HPLC grade H2O with 0.1% formic acid.  It is 
important to note that in the presence of methanol and acidic conditions, L-glutamic acid will 
form a methyl ester adduct (L-glutamic acid methyl ester). The stock solution and standard 
dilutions were made on the same day that standard curve and sample measurements were 
obtained. The standard stock solution mix underwent serial dilution to the desired concentrations 
with MPB diluent. The stock solutions ranged from 10 picomolar to 500 micromolar.  Standard 
curves were collected by injecting 1.25 microliters of standard onto the column, resulting in 
picomoles-on-column values ranging from 0.12 to 625 picomoles.  A separate internal standard 
stock solution of 10 mM DHBA was made HPLC grade methanol solution containing 1N HCl 
(2.5%) and ascorbic acid (1 mg/mL) to serve as the internal standard during extraction. DHBA 
internal standard stock solution was stored at -80˚C between extractions. 
5.3.3 Chromatographic Instrumentation and Software.
4
 
LC-MS/MS experiments were conducted on a Waters Acquity (Waters Co., Milford, 
MA, USA) UPLC whose effluent was directed into the electrospray source of a Waters Quattro 
Premier XE tandem quadrupole mass spectrometer. Both instruments were controlled and data 
acquired using Waters MassLynx 4.1 SCN 805 software. Peak integration and analyte 
quantitation was accomplished using Waters Quanlynx 4.1 software. 
                                                 
4
 Sections 5.3.3-5.3.6: Details provided in part by Dr. Robert Winefield, Director of Analytical Core, KUMC 
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5.3.4 Chromatography conditions. 
Brain extract samples and mixtures of purified neurochemicals used for external 
calibration (1.25 µL) were applied to a Waters BEH-Amide HILIC column (1.7 µm particle size, 
2.1 x 150 mm) protected by a Waters BEH-Amide Vanguard pre-column. DA and 5-HT levels 
were assessed with 5 μL injections of undiluted extract and GABA and Glut levels were assessed 
with 2.5 μL injections of diluted extract. Subsequent to loading the initial injection conditions 
(300 µL/min, 100% MPB, 30 ºC) were maintained for 1 minute (and the effluent directed to 
waste) to desalt the sample, then the compounds were resolved with a convex gradient (MPB 
decreasing to 70% over 5 min at 300 µL/min). The column was washed at 70% MPB at 1 
mL/min for 30 seconds before being ramped to 100% MPB (1 mL/min) in 11 sec and re-
equilibrated at 100% MPB (1 mL/min) for 38 seconds. Finally, the flow rate was decreased to 
300 µL/min (100% MPB) over 51 seconds. The total chromatographic run-time was 7.5 minutes. 
Quality control runs of standard solutions and blank solutions were run after every 12
th
 sample in 
order to confirm proper chromatographic performance and assess whether residual compound 
was present.  
5.3.5 Mass Spectra Acquisition. 
The column eluent was directed (via a divert valve) into the electrospray source of a 
Waters Quattro Premier XE tandem quadrupole mass spectrometer that was operated in positive 
ion mode. The following electrospray and collision-induced ionization parameters were 
maintained throughout the experiment: Source block and desolvation gas temperatures were set 
to 100°C and 350°C. The N2 (g) flow through the source block and ESI probe’s desolvation 
assembly were 50 L/h and 350 L/h respectively. The 1st and 3rd quadrupoles were tuned to an 
average resolution of 0.93 amu at full width, half-height. Argon gas pressure in the collision cell 
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was maintained at approximately 6x10
-3
 mbar such that the ion beam was consistently attenuated 
by 30%. Pre-programmed multiple ion monitoring was used to quantify the analytes and the 
parameters of this program (parent ion, product ion, optimized cone voltage, and collision 
energy) for each compound are reported in Table 4.1. 
5.3.6 Biological sample preparation and extraction.  
Whole mouse cerebellum and frontal cortex tissue was isolated from GKO and WT mice 
and immediately placed in liquid N2 and stored at -80˚C for future use.  Individual tissue was 
allowed to thaw while being weighed and was subsequently placed in 160 μL of MPB containing 
DHBA internal standard (50 μM final concentration).  Approximately whole cerebellum and 
approximately 50 mg of cortex tissue was used for extraction. The tissue was then homogenized 
well and underwent sonication for 30 seconds (12-13 pulses).  Finally, 60 μL of MPB was used 
to wash the sides of the tube and the sample was spun at 16,100 rcf for 10 minutes at 4˚C.  The 
supernatant was collected and used for analysis. Each extraction was handled individually and 
the resulting extract was immediately analyzed for neurotransmitter levels. All samples were run 
at room temperature. Due to the abundance of GABA and Glut in the tissue analyzed, primary 
extract was diluted 1:100 in MPB and mixed well prior to chromatographic separation and mass 
spectral analysis.  
5.3.7 Animals and Diet.  
GKO mice were generated as previously described and backcrossed into C57BL/6J for 
>12 generations (Xu, et al, JBC 2011; Wang, et al, BBA, 2011). Experiments were performed in 
non-diabetic females as specified in a protocol approved by the Institutional Animal Care and 
Use Committee at the University of Kansas Medical Center. GKO and WT mice were generated 
from heterozygous crosses and maintained in a pathogen-free facility at 24°C under a standard 
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12-hour light/12-hour dark cycle with free access to standard rodent chow (PicoLab 5053) and 
water. 
5.3.8 Statistical analyses.   
Linear regression analysis was used to determine linear response ranges for all analytes. 
Two (2)-way repeated-measures ANOVA analysis (genotype and tissue type) was performed for 
quantification of 5-HT, DA, GABA, and Glut levels in biological tissue extract. Duplicates were 












































6.1 PURPOSE AND SUMMARY OF FINDINGS 
 The work presented in this dissertation was conducted in order to characterize effects of 
genetic deficiency of NCB5OR in the mouse brain. Specifically, the studies aimed to 
characterize alterations in iron-related pathways, locomotor activity, and behavioral and 
molecular changes as they pertain to global regulation of metabolism and feeding and drinking 
behavior as a result of NCB5OR deficiency. Moreover, preliminary work was conducted to 
detect changes in neurotransmitters in the affected tissue as a means to elucidate mechanisms 
that could potentially be responsible for the observed phenotypes.  The results presented 
demonstrate alterations in iron-related pathways, neurotransmitter levels, locomotion, locomotor 
response to dietary iron deficiency, and altered behavior associated with those regions in which 
NCB5OR was absent, suggesting that NCB5OR plays an indirect role in maintaining the 
integrity of neurological function.  
6.1.1. NCB5OR contributes to pathways responsible for proper maintenance of iron homeostasis 
in neurological tissue.  
 The primary aims for studies in Chapter 2 were: 1.) To investigate the effects of 
NCB5OR deficiency on iron pathways in neural tissue. 2.) To investigate the interaction of 
dietary iron deficiency and genetic disruption of iron pathways in the cerebellum and midbrain 
on locomotion. We employed a number of molecular techniques as well as locomotor 
measurements to characterize dietary iron deficiency in mice lacking NCB5OR in the cerebellum 
and midbrain.  Data presented in this chapter detailed changes in mRNA transcript and protein 
levels for elements critical to maintenance of iron homeostasis as a result of NCB5OR 
deficiency. In addition, mice lacking NCB5OR in the cerebellum and midbrain displayed altered 
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locomotion under normal conditions as well as deficits in locomotion as a result of dietary iron 
deficiency.  
The response of CKO mice to dietary iron deficiency provides valuable insight into 
genetic and environmental interaction.  Specifically, loss of NCB5OR in the cerebellum and 
midbrain produced an opposite reaction to dietary iron deficiency than that of their WT 
counterparts.  Compared to chow fed controls, dietary iron deficiency elicited a hyperactive 
response in WT mice while CKO mice became hypoactive. Neurological conditions such as 
attention deficit/hyperactivity disorder (ADHD) and restless leg syndrome (RLS) are thought to 
be complex in that there are genetic and environmental influences that appear to contribute to the 
conditions.  The NCB5OR model demonstrates this interaction between genetic background and 
environmental influence in a manner that could help better understand the complex nature of 
such diseases.  
6.1.2. NCB5OR maintains the integrity of neurological systems responsible for eating and 
drinking behavior. 
The work presented in Chapter 3 aimed to investigate the underpinnings of metabolic and 
feeding phenotypes observed in mice globally deficient for NCB5OR.  The contribution of the 
cerebellum and midbrain to feeding and metabolic regulation has been well established. 
Therefore, we investigated whether loss of NCB5OR in the cerebellum and midbrain could 
contribute to previously described phenotypes of global knockout mice. Measurements from an 
indirect-calorimetry-based metabolic cage system revealed an increase in whole body glucose 
utilization, decreased voluntary exercise, and decreased thirst response in male CKO mice.  In 
addition, male CKO mice had lowered hydration ratios, increased fasted feeding weight gain, 
and increased serum leptin levels.  
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The presence of sexual dimorphism in the NCB5OR model has been observed in a 
number of different phenotypes, with males dominating the phenotypic presentation in both 
severity and onset. We hypothesize that the sexual dimorphism in the CKO mouse model results 
from estrogen modulation of brain bioenergetics. However, significantly more work is needed to 
better understand the specific contribution of sex to NCB5OR-related phenotypes.  
6.1.3 NCB5OR influences pathways responsible for balance of neurotransmitters. 
Chapter 4 delivered data surrounding preliminary investigation of neurotransmitter 
changes as a result of NCB5OR deficiency. The use of HILIC UPLC-MS/MS to analyze extract 
from the cortex and cerebellum of NCB5OR global knockout mice revealed significantly 
elevated levels of dopamine in the cortex.  This observation helps support preliminary data 
discussed in Chapter 1 that outlines hyperactivity in GKO mice.  Changes in dopaminergic 
function are thought to lie at the heart of hyperactive phenotypes and have also been linked to 
iron deficiency.   
It is important to note that GKO mice, which present with mild to moderate anemia and 
generalized iron deficiency, present with a hyper active phenotype that corresponds with 
elevated dopamine levels in the cortex.  In contrast, the CKO mouse response to generalized iron 
deficiency is hypoactive. The reversal in response due to regional restriction of NCB5OR 
deficiency helps support previous studies indicating mesocorticolimbic function and associated 
dopaminergic tracts in hyperactive phenotypes. 
6.2 LIMITATIONS 
Regionally restricted disruption of NCB5OR provides a powerful tool for focused 
assessment of phenotypes; however behavioral phenotyping provides simplified views of effects 
on a number of complex neural pathways.  The methods presented in this dissertation can 
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provide insight into, but not directly pinpoint, the exact pathways and modalities being affected 
by NCB5OR deficiency.  For example, the widened stance width and changes in gait may not 
reflect purely proprioceptive changes, but could be complicated by or a reflections of vestibular 
dysfunction. Therefore these data stand only as initial insights into possible pathways and 
processes being affected by deletion of NCB5OR in the cerebellum and midbrain.   
We observed no histological abnormalities in CKO mice as old as 16 weeks of age, 
indicating that the defects we observed were either of pathway dysfunction or progressive, but 
subtle, neurodegeneration.  Our current histological approach focused on observing gross 
histological changes in the CKO cerebellum, namely overt signs of Purkinje cell number loss and 
atrophy of the molecular or granular layers. While we did not observe these changes initially, it 
is still possible that a careful stereotactic study of the CKO cerebellum would reveal regional and 
layer-specific signs of neurodegeneration.   
These studies focused on CKO mice from 3 to 16 weeks of age, making the findings 
limited to that of early life.  Neurodegenerative processes are generally progressive and usually 
do not present until the mid or later years of life. This should serve as a caution to the reader 
when assessing the impact of NCB5OR deficiency, as there may phenotypes, ranging in severity, 
that arise as a function of age.   
6.3 FUTURE DIRECTIONS 
Our current data clearly demonstrates dysfunctional neuronal pathways as a result of 
NCB5OR deficiency. The means by which these deficits occur have yet to be explored, leaving a 
number of questions unanswered. There are three important questions that are directing plans for 
future studies into the effects of NB5OR deficiency on neural tissue. 
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1.) What are the physiological effects of NCB5OR deficiency on action potential and signal 
transduction in neurons? 
 Current data suggests that NCB5OR maintains pathways critical to iron homeostasis, 
however microarray data suggests that NCB5OR deficiency results in changes in a myriad of 
pathways.  Notably, there are significant changes in pathways responsible for maintenance of 
calcium homeostasis.  Calcium is a cornerstone in the neuronal membrane potential, action 
potential, and signal transduction.  Using single neuron recording, we aim to explore the effects 
of NCB5OR deficiency on neuron physiology and response to external cues.  
2.) What are the bioenergetic ramifications of NCB5OR deficiency in neurons and glial 
cells? 
 Previous studies of NCB5OR deficiency have detailed abnormal fatty acid metabolism, 
altered mitochondrial ETC complex function, and changes in mitochondrial morphology and 
number.  While the brain does not oxidize fatty acids energy, these observations point to altered 
bioenergetic pathways in NCB5OR deficient tissue.  We did not observe increased 2-DoG uptake 
in the cerebellum of 16 week old CKO mice, however, this may reflect a compensating 
bioenergetic profile rather than a ‘normal’ bioenergetic state.  We aim to explore mitochondrial 
function, morphology, and number in order to better understand the effects of NCB5OR 
deficiency on bioenergetics in neural tissue. 
3.) Can NCB5OR deficiency protect against or postpone frataxin-deficiency related iron 
deposition and cell death? 
 Friedreich’s ataxia arises through dorsal root ganglia degeneration and subsequent loss of 
proprioception as a result of the mitochondrial protein frataxin.  The disease is generally 
accepted as arising through toxic iron dyshomeostasis and histological analysis of dorsal root 
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ganglia from patients shows iron deposition in mitochondria.  A number of mouse models have 
arisen and model the disease fairly well.  Our data indicate that NCB5OR deficiency results in 
iron dyshomeostasis, most likely in the form of altered iron storage and labile iron pool 
maintenance.  In addition, loss of NCB5OR in the cerebellum results in elevated frataxin 
transcripts. We aim to investigate whether NCB5OR deficiency might prove beneficial in 
delaying the onset of phenotypes in mouse models of Friedreich’s Ataxia and help to provide 
more insight into the role of cytosolic iron homeostasis and mitochondrial interaction in the 
pathology of the disease. 
6.4 SIGNIFICANCE OF WORK 
Findings presented in this dissertation are important when exploring two main concepts: 
1) the specific contribution of NCB5OR to the integrity of neurological function and 2) the 
importance of genes whose function either directly or indirectly maintains bioenergetic 
homeostasis in the contribution to neurological disease.  It is hoped that this work will aid in the 
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APPENDIX I: DEFINITIONS AND EQUATIONS 
Average Respiratory Quotient: Mean respiratory quotient as calculated by 
RQ  = CO2 expelled  / O2 consumed 
Average vH2O: Mean respiratory H2O expulsion. Measured in milliliters per minute.  
Average vO2: Mean respiratory O2 consumption. Measured in milliliters per minute.  
Free Water: Water contents of the bladder.  
Gait symmetry: (Right forelimb + left forelimb step frequency) / (Right hind limb + left hind 
limb step frequency).  Presented as a real number. 
Hydration Ratio: [(Total Water–Free Water) / Lean Mass]  
LOD: A peak S/N:RMS less than 3. 
LOQ: A peak signal to noise ratio root mean squared (S/N:RMS) of ten 10 or greater.   
Max ∆A/∆T: How quickly the limb is loaded during the initial period of stance; how rapidly does 
the animal decelerate. Measured in square centimeters per second. 
Midline distance: Distance between the centroid of a paw at peak stance and a reference line 
drawn through the transverse midline of the animal. Measured in centimeters.  
MPP = [(10 – 17 Hz) / (0 – 25 Hz)]  x 100.   
Paw drag: Area under the curve from time of full stance to the time the paw lifts off from the 
belt. Measured in square millimeters. 
Paw overlap distance: Were paws to have been painted and paw prints made, ipsilateral fore and 
hind paws can become somewhat superimposed. This represents the distance between ipsilateral 
fore and hind paws if not superimposed. Measured in centimeters. 
Pedestrian Activity: All non-wheel running locomotion as measured by beam breaks in the 




RE = [(Theoretical value – Actual value) / Theoretical value] * 100. Presented as a percentage. 
Resting Energy Expenditure: Mean value for 30 minute periods with lowest energy expenditure. 
Measured in kcal/hr.  
Stance Width: The perpendicular distance between the centroids of either set of axial paws 
during peak stance. Measured in centimeters. 
Step angle: The angle made between left and right hind paws as a function of stride length and 
stance width. Measured in degrees. 
Swing duration: Time duration of the swing phase (no paw contact with belt). Measure in 
milliseconds.  
Systemic Metabolism: Energy expenditure and substrate utilization measured by O2 consumption 
and CO2 production.  
Total Energy Expenditure: Summed energy expenditure for entire cycle. Measured in kcal/hr.  
Total Water: Free water and water content of lean tissue.  
Wheel Running Activity: All wheel running locomotion as measured by the running wheel in the 












APPENDIX II: THE STRUGGLE 
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